| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
IceCure Medical Ltd.$3.65
-0.06 (-1.56%)
F 9Pipeline Score MedTech · Clinical
Market Cap
16.14 M
EPS
-0.23
P/E Ratio
-
Value Trade
494.81 K
-2.08 %
Week
-32.86 %
1 Month
-60.83 %
3 Month
-63.22 %
6 Month
-85.31 %
5 Year
17.5 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
127.53 K
52 Week Range
0.22 - 1.40
% held by Insiders
55.73 %
% held by Institutions
3.84 %
Enterprise Value
8.17 M
Total Shares
81.20 M
Short %
0.83 %
Float Shares
39.14 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F9
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 6%
Micro Cap (rank 857 of 911)
Percentile RankIceCure Medical Ltd. has significant pipeline risk (9/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ProSense® | kidney cancer | — | 2026-05-19 | recurrence free rate kidney cancer: 89.4%; recurrence free rate median follow up: 83.9%; median follow up years: 4.0; no residual cancer breast cancer: 100% Read More | IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked Read More | |
ProSense® | kidney cancer | — | 2026-05-19 | recurrence free rate kidney cancer: 89.4%; recurrence free rate median follow up: 83.9%; median follow up years: 4.0; no residual cancer breast cancer: 100% Read More | IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked Read More | |
ProSense® | kidney cancer | — | 2026-05-19 | recurrence free rate kidney cancer: 89.4%; recurrence free rate median follow up: 83.9%; median follow up years: 4.0; no residual cancer breast cancer: 100% Read More | IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ICCM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ICCM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ICCM▼ -14%on this news· ran to -27% by day 3
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
IceCure Medical has reported increased commercial adoption of its ProSense™ cryoablation technology in Brazil following FDA clearance for treating early-stage breast cancer. The company highlighted this growth at the SOBRICE Onco 2026 conference, where leading experts discussed ongoing clinical studies. ProSense™ is gaining traction as a minimally invasive alternative to traditional surgical methods.
Read more →ICCM▼ -24.5%on this news· ran to -48% by day 3
IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
IceCure Medical Ltd. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. This compliance was confirmed after the company's stock price remained at $1.00 or higher for ten consecutive business days. The matter is now considered closed by Nasdaq, reflecting positively on IceCure's market standing.
Read more →ICCMIceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
IceCure Medical has highlighted a new peer-reviewed article in the International Journal of Surgery, showcasing the advantages of cryoablation over radiofrequency ablation for early-stage breast cancer. The article emphasizes cryoablation's strong clinical outcomes and procedural benefits, including shorter procedures and minimal scarring. IceCure is preparing for the upcoming Japanese Breast Cancer Society meeting and plans to submit ProSense® for regulatory approval in Japan.
Read more →ICCM▼ -29.4%on this news· ran to -40% by day 1shared move
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor
IceCure Medical Ltd. has announced a private placement of $5.5 million with a healthcare-focused institutional investor. The offering includes ordinary shares and warrants priced at $3.00 each, above the previous market price. The proceeds will be used for working capital and corporate purposes, with the closing expected shortly, subject to customary conditions.
Read more →ICCM▲ +200.5%on this newsshared move
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
IceCure Medical reported a 70% increase in its U.S. active commercial install base for ProSense® breast cancer cryoablation following FDA clearance. This growth is attributed to heightened physician demand, clinical guideline support, and increased patient awareness. The company has successfully expanded its presence in major U.S. cities and generated more sales leads at medical conferences.
Read more →ICCM▲ +200.5%on this newsshared move
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Signi
IceCure Medical Ltd. reported a 70% increase in its U.S. active commercial install base for its ProSense cryoablation system following FDA marketing authorization. The growth is attributed to rising physician demand, clinical acceptance, and greater patient awareness. The company has gained strong interest at medical society conferences, generating significantly more sales leads compared to previous years. ProSense is positioned as an effective treatment option for low-risk breast cancer patients, especially those unsuitable for surgical interventions.
Read more →ICCM▼ -30.9%on this news
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
IceCure Medical Ltd. announced a 1-for-30 reverse share split to regain compliance with Nasdaq's minimum bid price requirement. This decision, approved by shareholders, aims to increase the trading price of its ordinary shares. The split will take effect on June 4, 2026, and will not alter shareholders' percentage ownership interests.
Read more →ICCMIceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
IceCure Medical presented promising data at ECIO 2026, highlighting a 89.4% recurrence-free rate for kidney cancer patients treated with ProSense®. An independent study reported no residual cancer in breast cancer patients at 6 and 12 months post-procedure. The FDA clearance of ProSense® is driving global interest in cryoablation as a minimally invasive treatment option.
Read more →ICCMIceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
IceCure Medical Ltd. has received a 180-day extension from Nasdaq to comply with the minimum bid price requirement. The company did not regain compliance during the initial period but has shown intent to cure the deficiency. The extension allows until November 9, 2026, for the company to meet the necessary criteria without immediate impact on its trading status.
Read more →ICCMIceCure Reports First Quarter 2026 Financial Results: ProSense Sales Increase Substantially in the U.S. and North America Pent-up demand immediately following FDA clearance generates 46% increase in active customer accou
IceCure Medical Ltd. reported a notable financial performance for the first quarter of 2026, driven by a significant increase in ProSense sales in North America after the FDA clearance. Active customer accounts utilizing ProSense rose 46%, reflecting strong demand and successful regulatory milestones. Despite the positive revenue growth of approximately 26%, the company also reported a net loss of $4.27 million, which raises concerns about its ongoing financial health. The company plans to expand its sales efforts in the U.S. and conduct a post-marketing study to further boost ProSense adoption.
Read more →ICCM▼ -6.6%on this news
IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026
IceCure Medical Ltd. will announce its financial and operational results for Q1 2026 on May 12, 2026. The announcement will be made before the market opens, followed by a conference call at 11:00 a.m. EDT. The company specializes in cryoablation technology for tumor destruction, offering a minimally invasive alternative to surgery.
Read more →ICCM▼ -6.4%on this news· ran to -21% by day 3shared move
IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market
IceCure Medical showcased its ProSense® cryoablation system at the ASBrS 2026 Annual Meeting, emphasizing its role as a minimally invasive treatment for low-risk breast cancer. The company reported a significant increase in U.S. revenue for ProSense® systems and highlighted the growing clinical adoption of cryoablation. Experts at the symposium discussed the benefits of ProSense® in de-escalating breast cancer care, particularly for older patients.
Read more →ICCMDear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Special General Meeting of Shareholders (the “ Meeting ”) of IceCure Medical Ltd. (the “ Company ”), to be held on
IceCure Medical Ltd. has announced a Special General Meeting of Shareholders scheduled for May 11, 2026. At this meeting, shareholders will vote on a proposed reverse split of the company's ordinary shares. The board of directors has recommended that shareholders vote in favor of this proposal. Shareholders of record as of April 27, 2026, will be entitled to participate, either in person or through a proxy.
Read more →ICCMIceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025 The Company's participation at the Society of Breast
IceCure Medical has announced a significant increase in U.S. ProSense revenue of over 30% in the first quarter of 2026 compared to the prior year. The company's participation in the Society of Breast Imaging Symposium showcased their cryoablation technology, which is gaining traction among physicians and healthcare systems. A highlighted study at the symposium indicated that the ProSense system provides substantial cost savings compared to traditional treatments. The company anticipates continued growth as they expand their installed base of ProSense systems across prominent academic and research hospitals.
Read more →ICCM▼ -33.7%on this news· ran to -49% by day 3
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement
IceCure Medical Ltd. has announced a registered direct offering of 8 million ordinary shares at $0.50 each, aiming to raise approximately $4.0 million. Concurrently, the company will issue Series B and C warrants for additional shares. The proceeds will be used for working capital and general corporate purposes, with the offering expected to close on March 27, 2026.
Read more →ICCM▼ -7.3%on this news· ran to -56% by day 3shared move
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
IceCure Medical announced positive top-line results from its ICESECRET trial, showing an 89.4% recurrence-free rate for patients with small renal masses and no prior kidney cancer. The study included 114 patients and demonstrated an 83.9% recurrence-free rate overall. Results will be presented at the European Conference of Interventional Oncology in 2026, supporting the commercial adoption of ProSense® for kidney cancer treatment.
Read more →ICCMIceCure Appoints Meir Peleg as Chief Financial Officer
IceCure Medical Ltd. has appointed Meir Peleg as Chief Financial Officer, effective May 17, 2026. This decision aligns with the company's strong commercial momentum for its ProSense® cryoablation technology, which recently received FDA clearance for low-risk breast cancer. Additionally, IceCure plans to appoint Dr. Richard Fine as Medical Director to enhance clinical initiatives. The company is also searching for a new Chief Technology Officer following the departure of its current VP of R&D.
Read more →ICCM▼ -5.1%on this news
IceCure Reports 2025 Full Year Financial & Operational Results
IceCure Medical reported record sales for 2025, driven by FDA clearance for its ProSense® cryoablation technology for low-risk breast cancer. The company plans to expand its commercial infrastructure and launch a post-marketing study across 30 clinical sites. Despite a decrease in gross profit, the overall commercial momentum and positive recommendations from medical societies indicate a favorable outlook for the company's growth.
Read more →ICCM▲ +8.9%on this news
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense Cryoablation in the Local Treatment of Low-Risk Breast Cancer IceCure is engaged with leading medical institutions throughout the U.S. looking to par
IceCure Medical has received FDA approval for the post-marketing "ChoICE" study, focusing on the use of its ProSense cryoablation technology for low-risk breast cancer treatment. The study aims to enroll approximately 400 patients across 30 clinical sites within 36 months, beginning in late 2026. This progresses after the FDA granted marketing authorization for ProSense for certain breast cancer patients in October 2025. The initiative is backed by established reimbursement codes, aimed to facilitate broader access to the treatment.
Read more →ICCMIceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026
IceCure Medical Ltd. announced that it will release its 2025 full-year financial and operational results on March 17, 2026. The company will issue a press release before the Nasdaq Stock Market opens and will host a conference call to discuss these results. IceCure Medical focuses on developing cryoablation technology for tumor destruction and has a global presence with its ProSense system.
Read more →ICCMAmerican Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer
IceCure Medical's ProSense® cryoablation system has been recommended by the American Society of Breast Surgeons (ASBrS) for low-risk early-stage breast cancer in its updated 2026 Resource Guide. This endorsement follows the FDA's clearance of ProSense® in October 2025, marking it as the first FDA-approved device for this patient demographic. The guidance aims to enhance awareness and adoption of cryoablation among healthcare professionals.
Read more →ICCM▲ +10.1%on this news
IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas
IceCure Medical announced the publication of an independent study in PLOS One, demonstrating the effectiveness of ProSense® cryoablation for treating fibroadenomas. The study showed a significant volume reduction of 92.9% at one year post-treatment and may influence future treatment guidelines. This research highlights the potential of cryoablation as a safer, minimally invasive alternative to surgical excision for benign breast tumors.
Read more →ICCMIceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026
IceCure Medical has completed the five-year follow-up evaluation of its ICESECRET clinical trial for ProSense®, a cryoablation treatment for small renal masses in kidney cancer patients. Interim data showed an impressive 88.7% recurrence-free rate, highlighting ProSense® as a safe and effective option. The final analysis is expected in the second quarter of 2026.
Read more →ICCMIceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation
IceCure Medical has announced that Thomas Hospital in Fairhope, Alabama, has installed the ProSense® cryoablation system, becoming the first facility in the state to offer this treatment for breast cancer. The installation follows FDA marketing authorization for the system in treating low-risk breast cancer. The first procedures are expected to begin in the coming weeks, and are made possible through funding from the Thomas Hospital Foundation. This development marks a significant advancement in breast care options for women in Alabama.
Read more →ICCMIceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®
IceCure Medical has announced that Shero Imaging in Missouri is the first clinic in the state to offer breast cancer cryoablation procedures using the ProSense® system, which recently received FDA marketing authorization. This innovative treatment option is aimed at low-risk breast cancer patients and is designed to be minimally invasive. The ProSense® system allows for effective tumor destruction through freezing, providing a new avenue for patient care.
Read more →ICCMIceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved
IceCure Medical Ltd. announced the planned departure of CFO Ronen Tsimerman after nearly ten years. Tsimerman will remain in his role until a successor is appointed to ensure a smooth transition. His leadership has been pivotal in achieving significant milestones, including the company's Nasdaq listing and FDA clearance of the ProSense® system for low-risk breast cancer.
Read more →ICCMIceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer
IceCure Medical announced that the American Society of Breast Surgeons (ASBrS) is updating its guidelines to include cryoablation for low-risk breast cancer treatment. This inclusion is expected to enhance the recommendation of cryoablation among breast surgeons, promoting its adoption as a standard of care. The guidelines reflect positive clinical evidence, including results from IceCure's ICE3 trial, which demonstrated the effectiveness of cryoablation. The anticipated changes are expected to lead to increased commercial interest and reimbursement support for cryoablation.
Read more →ICCM▼ -5.5%on this news
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense Sales Company experiencing strong demand in the U.S. following FDA marketing authorization of ProSense as the only on-l
IceCure Medical Ltd. reported record fourth quarter and full-year sales for its ProSense cryoablation systems in 2025, following FDA marketing authorization for low-risk breast cancer treatment. The company experienced strong demand in the U.S. and Europe, driven by the acceptance of ProSense in renowned medical institutions. Notably, independent investigators produced numerous peer-reviewed publications demonstrating the efficacy of ProSense for various cancer treatments. IceCure's innovative approach is positioned to enhance patient care while addressing a significant annual patient population.
Read more →ICCMAMENDED AND RESTATED ARTICLES OF ASSOCIATION OF ICECURE MEDICAL LTD. (The "Company") TABLE OF CONTENTS Article Subject Page 1. Preamble 1 2. Public company 2 3. Donations 2 4. Company's objectives 2 5. Limitation of liab
IceCure Medical Ltd. has amended and restated its Articles of Association. The document details the company structure, shareholder rights, and operational guidelines as stipulated in Israeli law. Among the amendments, the company outlines its objectives, limitations on liability, and processes for issuing shares and managing shareholder meetings. This documentation is crucial for ensuring compliance and providing a clear framework for the company's governance.
Read more →ICCM▲ +8.7%on this news
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer
IceCure Medical Ltd. anticipates record sales in North America for the fourth quarter, driven by the FDA's recent marketing authorization of its ProSense® system for treating low-risk breast cancer in women aged 70 and above. The company reports increased interest from medical institutions and patients, highlighting the system's non-surgical benefits. Preliminary revenue results are expected in January 2026.
Read more →ICCMIceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
IceCure Medical announced that four abstracts featuring independent studies on its ProSense® cryoablation technology were presented at the RSNA Annual Meeting 2025. These studies, involving 263 patients, demonstrate the effectiveness of ProSense® as a non-surgical option for breast cancer treatment. The findings support the growing adoption of this technology among medical professionals, especially following recent FDA marketing approval.
Read more →ICCMIceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
IceCure Medical has received a Notice of Allowance for a patent in China for its Cryogen Flow Control technology, which enhances the precision of cryoablation procedures. This innovation follows the FDA marketing authorization of its ProSense® system for treating low-risk breast cancer. The company aims to improve patient outcomes with its next-generation cryoablation systems, which are already approved for use in China.
Read more →ICCMIceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
IceCure Medical reported its financial results for the nine months ending September 30, 2025, highlighting a landmark FDA marketing authorization for its ProSense® cryoablation system. This approval is expected to boost demand among patients unsuitable for surgery. Despite a revenue decline and a net loss of $10.8 million, the company anticipates increased commercial traction and interest from healthcare providers. Upcoming catalysts include further installations and procedure volume growth.
Read more →ICCMIceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
IceCure Medical has received regulatory approval for its ProSense® Cryoablation System in Switzerland, allowing it to treat various cancers including breast, lung, liver, and kidney. This approval follows a recent FDA marketing authorization in the U.S. and is expected to enhance the adoption of ProSense® in European markets. The system offers a minimally invasive alternative to surgical tumor removal, leveraging liquid nitrogen for effective tumor destruction.
Read more →ICCMIceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
IceCure Medical Ltd. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. The company has 180 days to regain compliance, with the option for an additional period if necessary. The situation is being closely monitored, and the company is prioritizing its continued listing on Nasdaq.
Read more →ICCMIceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
IceCure Medical Ltd. will announce its financial and operational results for the nine months ending September 30, 2025, on November 19, 2025. The company will issue a press release before the market opens and host a conference call at 10:00 a.m. EST to discuss these results. IceCure specializes in minimally invasive cryoablation technology for tumor destruction.
Read more →ICCMIceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
IceCure Medical has promoted Shay Levav to Chief Operating Officer as the company prepares for increased commercial activities in the U.S. following FDA clearance for its ProSense® system. Levav will continue to oversee Regulatory Affairs, Quality Assurance, and Clinical Affairs. The ProSense® system is the first FDA-authorized device for treating early-stage, low-risk breast cancer with cryoablation.
Read more →ICCMIceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival
IceCure Medical's Cryoablation System, when combined with stereotactic body radiation therapy (SBRT), has demonstrated a 92% disease-specific 5-year survival rate for patients with non-small cell lung cancer (NSCLC). This combination therapy shows significantly improved outcomes compared to SBRT alone, which has a lower survival rate. The study, published in PLOS One, highlights the potential of this approach for inoperable patients with larger tumors.
Read more →ICCM▼ -6%on this news
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
IceCure Medical's ProSense® received FDA marketing authorization for treating low-risk breast cancer in patients aged 70 and above. This announcement follows the TME Fall Summit, where the product garnered significant interest from leading medical professionals. The ProSense® system offers a minimally invasive alternative to surgical tumor removal, enhancing patient recovery and reducing complications.
Read more →ICCMIceCure Medical to Attend the 2025 Maxim Growth Summit
IceCure Medical has achieved FDA marketing authorization for its ProSense® Cryoablation system, the first device approved for local treatment of early-stage, low-risk breast cancer in patients aged 70 and older. The company will participate in the Maxim Growth Summit in New York City on October 22-23, 2025, where management will meet with institutional investors to discuss recent milestones.
Read more →ICCMIceCure Receives FDA Marketing Authorization for ProSense Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above ProSense is the first and only medical device to be granted FDA marketing auth
IceCure Medical Ltd. announced that the FDA has granted marketing authorization for its ProSense cryoablation system, specifically designed for the local treatment of low-risk breast cancer in women aged 70 and above. This makes ProSense the first and only medical device authorized for this indication, providing a minimally invasive alternative to surgical tumor removal. The FDA's approval requires IceCure to conduct a post-market study with 400 patients to gather additional data. The company aims to leverage this authorization to expand its U.S. customer base and improve care standards for this patient demographic.
Read more →ICCMIceCure Medical
IceCure Medical has received FDA marketing authorization for ProSense®, a minimally invasive cryoablation treatment for early-stage low-risk breast cancer in women aged 70 and over. This marks the first significant innovation in local breast cancer treatment in decades, providing an effective outpatient procedure that minimizes recovery time and preserves breast cosmetics. The authorization follows the successful completion of the ICE3 trial, establishing safety and efficacy comparable to traditional lumpectomy. The FDA has mandated the company to conduct a post-market study to further assess long-term outcomes and safety.
Read more →ICCMIceCure's ProSense at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented IceCure's exclusive workshop was filled
IceCure Medical showcased its ProSense cryoablation technology at the European Society of Breast Imaging Congress 2025, highlighting early-stage breast cancer treatment advancements. The workshop attracted significant attention, emphasizing a trend towards de-escalation of care in cancer management. Five independent studies underscored ProSense's effectiveness and safety, with one researcher receiving recognition for her contribution to noninvasive biomarker research. The event focused on promoting minimally invasive options for improving patient outcomes in breast cancer treatments.
Read more →ICCMIceCure's ProSense Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented Presentations from 5 Key Opinion Leaders on ProSense cryoablation including 3 ind
IceCure Medical featured its ProSense cryoablation technology at the 2025 CIRSE Annual Meeting, presenting positive clinical results from four independent studies. The event highlighted the growing interest of interventional radiologists in expanding their practices to include breast cancer care. Live demonstrations of ProSense attracted a significant audience of medical practitioners. IceCure's CEO praised the ongoing research conducted by medical professionals, emphasizing the potential of ProSense in improving patient outcomes in oncology.
Read more →ICCMIceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense Cryoprobes The invention is designed to improve cryoprobe extraction, further reducing risk of tissue trauma, leading to lower costs and
IceCure Medical has been granted a Notice of Allowance from the U.S. Patent and Trademark Office for its next-generation XSense cryoprobes, aimed at enhancing cryoprobe extraction and minimizing tissue trauma. This innovative technology, which includes features such as a heater and temperature sensor, is designed to improve the safety and efficiency of cryoablation procedures. The XSense system recently received regulatory approvals in the U.S. and Israel and is positioned to enhance the company's offerings in minimally invasive tumor destruction. IceCure aims to further optimize patient outcomes through this patented advancement.
Read more →ICCM▲ +9.6%on this newsshared move
IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense Cryoablation System for Breast Cancer and Other Indications Approved for a broad range of indications including in gynecology, oncology and ge
IceCure Medical Ltd. has received regulatory approval from the Medical Device Division of Israel's Ministry of Health for its next-generation XSense cryoablation system. This system is designed to treat various tumors, including breast cancer, through a minimally invasive technique. Additionally, the XSense system has also received regulatory clearance in the United States for multiple indications. The approval reaffirms IceCure's leadership position in cryoablation technologies and is expected to drive commercial growth in the sector.
Read more →ICCMTwo New Publications from the Independent THERMAC Trial Featuring IceCure
IceCure Medical Ltd. announced two publications from the independent THERMAC Trial, showcasing positive results for their ProSense® cryoablation system in treating early-stage breast cancer. Published in reputable journals, the studies reported high patient satisfaction rates and superior cosmetic outcomes following thermal ablation compared to traditional surgical methods. The findings support the clinical validation of ProSense® and position it favorably for future phase III trials, emphasizing its efficacy and safety for patients.
Read more →ICCMIceCure's ProSense Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy Independent study reports pain scores declined from a median of 8 on a scale of 0-10 to a median of 0 for patients
IceCure Medical announced promising results from an independent study on its ProSense cryoablation system, which effectively treats abdominal wall endometriosis (AWE). The study found that pain scores for patients who underwent the procedure dropped dramatically from a median of 8 to 0. ProSense is FDA-cleared and approved in the EU for gynecological indications, demonstrating substantial procedural efficacy and offering a minimally invasive alternative to traditional treatments for endometriosis. The findings further support the commercial potential of ProSense in managing AWE and other gynecological conditions.
Read more →ICCMICECURE MEDICAL LTD. UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (U.S. dollars in thousands, except share data and per share data) As of June 30, As of
IceCure Medical Ltd. recently released its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025. The company experienced a net loss of $6,952,000, with accumulated losses reaching $112,331,000. IceCure also noted negative cash flows from operations amounting to $6,850,000. These financial difficulties have raised concerns regarding the company's ability to continue its operations without securing additional funding.
Read more →ICCMIceCure Reports Financial & Operational Results for the First Half of 2025
IceCure Medical Ltd. reported financial and operational results for the first half of 2025, highlighting a successful $10 million rights offering and positive FDA engagement regarding their ProSense® breast cancer treatment. The company anticipates FDA marketing authorization for ProSense® in women aged 70 and older and has noted an increase in product adoption in Europe. Despite a slight increase in net loss and revenue declines, IceCure remains optimistic about upcoming milestones and increased adoption of their treatment across various markets.
Read more →ICCMIceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
IceCure Medical Ltd. (NASDAQ: ICCM) has announced that it will release its financial and operational results for the first half of 2025 on August 13, 2025. The company will provide insights during a conference call scheduled for the same day, which highlights its commitment to stakeholder communication. IceCure is known for its minimally invasive cryoablation technology, primarily used for tumor destruction. This release will be closely monitored by investors and industry professionals for insights into the company's performance and future prospects.
Read more →ICCMIceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million
IceCure Medical Ltd. announced the expiration and results of its rights offering, which yielded approximately $10 million in gross proceeds and was two times over-subscribed. The offering allowed existing shareholders to purchase shares at a subscription price of $1.00 per unit. A total of 10,000,000 units were validly subscribed, highlighting strong interest from investors. The company plans to deliver shares and warrants resulting from the offering on or about July 30, 2025.
Read more →ICCM▲ +8.6%on this newsshared move
IceCure's ProSense Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoabl
IceCure Medical's ProSense technology was highlighted at the Japanese Breast Cancer Society Conference, showcasing impressive updated clinical data that indicates a 99% recurrence-free rate following cryoablation treatment. Professor Hisanori Kawamoto's independent study, which earned the conference's Best of Breast Cancer Award, emphasized the effectiveness of ProSense with a reported 0% local recurrence rate after five years. IceCure anticipates potential commercial success in Japan, collaborating with Terumo Corporation for regulatory approval in breast cancer treatment.
Read more →ICCMIceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period
IceCure Medical Ltd. has announced that the subscription period for its rights offering will expire on July 28, 2025. Rights holders can purchase units at a price of $1.00 each, with applications needing to be submitted through their brokers or dealers. The company emphasizes the importance of acting promptly as the rights will expire, and any unexercised rights will have no value. IceCure also engaged Maxim Group LLC as the dealer-manager for this offering.
Read more →ICCMDear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Annual and Special General Meeting of Shareholders (the “ Meeting ”) of IceCure Medical Ltd. (the “ Company ”), to
IceCure Medical Ltd. has invited its shareholders to attend the Annual and Special General Meeting scheduled for August 20, 2025. The meeting will discuss various matters, including the re-appointment of auditors and board members. Shareholders of record as of July 23, 2025, will have the right to vote either in person or via proxies. The board of directors is recommending a vote in favor of all listed proposals.
Read more →ICCMIceCure Announces Commencement of Rights Offering
IceCure Medical Ltd. has announced the commencement of a rights offering aimed at raising up to $10 million in gross proceeds. Shareholders of record as of July 9, 2025, are being provided with non-transferable subscription rights to purchase units at a price of $1.00 per unit. Epoch Partner Investments, the company’s largest shareholder, is committed to participate in the offering. The rights offering will expire on July 28, 2025, unless extended, and the proceeds will be used primarily for repaying a bridge loan and for general corporate purposes.
Read more →ICCMIceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
IceCure Medical Ltd. announced preliminary financial results for the three and six months ending June 30, 2025. The company expects product sales of $525,000 for the quarter, a decline compared to $1.65 million for the same six-month period in 2024. Delayed shipments, primarily for non-U.S. customers, are expected to resume, but these setbacks have contributed to a decrease in projected sales. IceCure plans to release comprehensive financial results in August 2025.
Read more →ICCMIceCure Reports Preliminary Financial Results for the Three and Six Months Ended
IceCure Medical Ltd. reported preliminary financial results for the three and six months ended June 30, 2025, revealing expected product sales of approximately $525,000 for the quarter. Despite dealing with shipment delays for some non-U.S. customers, the company noted that the U.S. market was unaffected due to managed inventory levels. However, total product sales for the first half of 2025 reflected a decline compared to prior year figures, highlighting potential fluctuations in order flow and sales. The company plans to release comprehensive financial results in August 2025, with the current estimates still subject to final auditing processes.
Read more →ICCMIceCure Announces Record Date for Rights Offering for Up to $10 Million
IceCure Medical Ltd. announced a rights offering to raise up to $10 million, allowing current shareholders to subscribe for additional units. The offering is scheduled to occur with a record date of July 9, 2025, and an expiration date of July 28, 2025. Epoch Partner Investments, the company's largest shareholder, has committed to fully exercise its subscription rights, reinforcing its support for IceCure's strategy. The funds will be used to repay a $2 million loan and for general corporate purposes.
Read more →ICCMIceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA's marketi
IceCure Medical Ltd. announced the receipt of a Notice of Patent Allowance from the USPTO for its Cryogen Flow Control technology. This innovation aims to enhance the efficiency of their cryoablation procedures, which are alternatives to surgical tumor removal. The patent build-up comes as IceCure awaits FDA marketing approval for its ProSense system in early-stage breast cancer, emphasizing their commitment to expanding treatment indications. The patent, effective until 2045, also supports the anticipation of increased commercial traction in the market.
Read more →ICCM▼ -8.8%on this news
IceCure Medical Reports First Quarter 2025 Financial Results Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense in women aged 70+ with earl
IceCure Medical has reported its first-quarter 2025 financial results and shared a proposed post-market study plan with the FDA for its ProSense system. The company anticipates a positive marketing authorization decision for ProSense, aimed at treating early-stage low-risk breast cancer in women aged 70 and over. They experienced year-over-year sales growth in North America, alongside a supportive investment from a board member. However, the overall sales showed a slight decline, impacting gross profits and margins.
Read more →ICCMIceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
IceCure Medical Ltd. has announced the release of its financial and operational results for Q1 2025, scheduled for May 28, 2025. The company, known for its cryoablation technology that targets tumors through freezing, will provide these results before the opening of the Nasdaq Stock Market. A conference call to discuss the results and other developments will be hosted at 10:00 a.m. EDT on the same day.
Read more →ICCMIceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation
IceCure Medical Ltd. has garnered significant interest from breast surgeons in its ProSense® cryoablation technology at the ASBrS 2025 Annual Meeting. Following a positive FDA development regarding marketing authorization, many doctors inquired about participating in IceCure's upcoming post-market study. The technology was positively featured in key presentations, emphasizing its potential benefits in treating early-stage breast cancer. The company aims to conclude a study plan with the FDA to further validate ProSense® for use alongside endocrine therapy in older women.
Read more →ICCMIceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense Cryoablation in Women 70+ with Early-Stage Breast Cancer Final marketing authorization decision for early-
IceCure Medical announced a productive meeting with the FDA regarding the marketing authorization of its ProSense Cryoablation technology, aimed at treating early-stage breast cancer in women aged 70 and above. The FDA has requested a post-market study plan, which IceCure is expected to submit soon, involving a minimum of 400 patients across 25 sites. This study aims to provide additional data to support the treatment's adoption. The company views this as a significant step towards making minimally invasive treatment options available for more patients.
Read more →ICCMIceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
IceCure Medical Ltd. participated in the Society of Breast Imaging (SBI) 2025 Breast Imaging Symposium, sponsoring hands-on training courses featuring its ProSense® cryoablation technology. The sold-out events underscored the growing interest among radiologists for integrating this minimally invasive technique into their practice. Dr. Robert C. Ward, a prominent user of ProSense®, highlighted its effectiveness in treating breast tumors. IceCure's CEO expressed confidence in the alignment of the company's mission with SBI's focus on early detection of breast cancer.
Read more →ICCMIceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific session Independent studies of ProSense® featured in scientific ...
IceCure Medical's ProSense® technology was a highlighted topic at the European Conference on Interventional Oncology 2025, focusing particularly on its application in breast cancer cryoablation. Independent studies presented showed high patient satisfaction and efficacy, with ProSense® emerging as a preferred treatment option over traditional methods. The conference featured multiple scientific sessions and hands-on training, showcasing increasing interest and confidence in minimally invasive cancer treatments. IceCure's CEO emphasized the growing adoption of their technology in Europe and beyond, suggesting a strong market potential for ProSense®.
Read more →ICCMDear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Special General Meeting of Shareholders of IceCure Medical Ltd. (the " Meeting "), to be held on Thursday
IceCure Medical Ltd. has announced a Special General Meeting for shareholders scheduled on May 15, 2025. At this meeting, shareholders will vote on several agenda items, including the renewal of the Compensation Policy and equity-based compensation grants for key executives. The board of directors is urging shareholders to vote in favor of all proposals outlined in the notice for the meeting. Only shareholders on record as of April 16, 2025, are eligible to vote or appoint proxies for representation at the meeting.
Read more →ICCMIceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense Cryoablation Sales in North America Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy P
IceCure Medical announced a noteworthy 42% increase in sales of its ProSense cryoablation system for 2024, primarily driven by North American sales. The company is awaiting an FDA decision regarding marketing authorization for ProSense as a treatment for early-stage low risk breast cancer. Despite positive trends, IceCure reported a slight increase in net loss, and challenges remain in certain international markets. The CEO highlighted encouraging signs of market adoption and ongoing interest in cryoablation therapies.
Read more →ICCMIceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate IceCure Medical Ltd. (Nasdaq: ICCM) ( IceCure , IceCure Medical or the Company ), developer of minimally-invasive cryoablation technology that...
IceCure Medical presented interim results from its ICESECRET study at the European Association of Urology Conference, highlighting the efficacy of its ProSense® cryoablation technology for patients with small renal masses. The study indicated an impressive 88.7% recurrence-free rate in tumors sized ≤3 cm after a mean follow-up of approximately three years. The study evaluated 111 patients, showing cryoablation as a viable and safe option for those ineligible for kidney-preserving surgery.
Read more →ICCMIceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
IceCure Medical Ltd. has announced that it will report its financial and operational results for the year ending December 31, 2024, on March 27, 2025. The announcement includes details about a conference call and webcast scheduled for the same day. IceCure Medical specializes in minimally invasive cryoablation technology for tumor destruction, focusing on various cancer types. The upcoming results release is anticipated to provide insights into the company's performance and future developments.
Read more →ICCM▼ -15.5%on this newsshared move
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense Cryoablation in Early-Stage Breast Cancer IceCure working in close collaboration with FDA towards De Novo decision
IceCure Medical Ltd. is continuing its discussions with the FDA about marketing authorization for its ProSense cryoablation system aimed at treating early-stage low-risk breast cancer. The company anticipates a decision from the FDA after the first quarter of 2025. The FDA convened an Advisory Panel which voted positive on the benefit-risk profile of ProSense. The ongoing collaboration highlights the importance of public health discussions involving various stakeholders.
Read more →ICCMIceCure's ProSense Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference IceCure exhibited at the prestigious event in Vienna, Austria attended by oncologists, breast surgeon
IceCure Medical Ltd. recently showcased its ProSense Cryoablation technology at the St. Gallen International Breast Cancer Conference in Vienna, Austria. The company highlighted six peer-reviewed studies demonstrating the efficacy and safety of its cryoablation system, which offers a minimally invasive option for tumor destruction. The studies received significant interest from conference attendees, further illustrating the increasing traction of ProSense in the market. IceCure aims to advance women's health through innovation and collaboration among medical practitioners.
Read more →ICCM▲ +7%on this newsshared move
IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology This latest IP win rounds out protection for the cryogenic pump in major global market following grants f
IceCure Medical Ltd. has achieved a Notice of Allowance from the China National Intellectual Property Administration for its novel cryogenic pump designed for cryoablation technology. This development complements previously granted patents in the U.S., Europe, and Japan, broadening the company's market protection. The new cryogenic pump distinguishes itself by being submersible in liquid nitrogen while facilitating effective temperature control during procedures. IceCure's advancements aim to expand their range of devices, enhancing the safety and efficacy of tumor destruction treatments across multiple indications.
Read more →ICCMBreast Cancer Patients who Underwent IceCure's ProSense Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery Independent study published in Gland Surgery a
IceCure Medical Ltd. (Nasdaq: ICCM) announced that an independent study published in Gland Surgery highlighted significantly higher patient satisfaction with its ProSense Cryoablation compared to standard breast cancer surgery. Conducted by experts at Kameda Medical Center in Japan, the study emphasizes the importance of health-related quality of life in treatment planning. The CEO expressed optimism that the findings will aid their distribution partner, Terumo Corporation, in seeking regulatory approval for the device in Japan.
Read more →ICCMIceCure Submits Filing for Regulatory Approval of its Next-Generation XSense Cryoablation System in Israel Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in
IceCure Medical has submitted a filing for regulatory approval of its XSense cryoablation system to Israel's Ministry of Health. This system serves a broad range of indications and aligns with the global trend toward de-escalated surgeries and minimally invasive techniques. Having already secured FDA clearance, the company is optimistic about receiving approval in Israel in the coming months as demand for such procedures is expected to rise. However, the pending nature of AMAR's decision introduces some uncertainty regarding market entry.
Read more →ICCMIceCure's ProSense in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authoriza
IceCure Medical participated prominently at the Society of Interventional Oncology Annual Meeting, showcasing its ProSense cryoablation technology. Independent studies presented during the event highlighted the safety and efficacy of ProSense for breast cancer treatment. An abstract from the Netherlands received the highest score in its category, pushing for further clinical trials comparing cryoablation with traditional surgery. The CEO of IceCure emphasized growing interest from physicians in the U.S. as the FDA's decision on market authorization is anticipated.
Read more →ICCMIceCure Files for Regulatory Approval of ProSense Cryoablation System in China Seeks to expand regulatory approval in China where IceSense3 has already been approved
IceCure Medical Ltd. has filed for regulatory approval in China for its ProSense Cryoablation System, aiming to enhance its presence in the growing cryoablation market. This system is designed for various surgical fields including general surgery, oncology, and urology. ProSense's application expands upon the existing IceSense3 approval by introducing new cryoprobes, potentially increasing treatment accessibility. The company's CEO highlights the importance of securing reimbursement to effectively enter this significant market.
Read more →ICCM▼ -10%on this news
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense Sales for 2024 in North America Increase in sales of ProSense , based on preliminary unaudited results, demonstrate growing adoption
IceCure Medical reported a 42% increase in ProSense sales for 2024 in North America, emphasizing growing adoption of its minimally invasive cryoablation technology. In a letter to shareholders, CEO Eyal Shamir highlighted key achievements such as a successful conclusion to the ICE3 study and a favorable vote from the FDA's Advisory Panel for early-stage breast cancer treatment. The company has expanded its Board of Directors and is optimistic about executing market opportunities in 2025, following discussions with the FDA regarding upcoming marketing authorization decisions.
Read more →ICCM▲ +5.4%on this news
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule
IceCure Medical Ltd. has announced that it has regained compliance with the Nasdaq minimum closing bid price requirement after its shares sustained a bid price of $1.00 or more for at least 10 consecutive business days. This confirmation by Nasdaq signals that the prior compliance deficiency is now resolved. Consequently, IceCure is fully compliant with all listing requirements and will continue to trade on The Nasdaq Capital Market.
Read more →ICCM▲ +5.7%on this newsshared move
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology XSense system's innovative cryogenic connector technology designed to improve safety and maintain the int
IceCure Medical Ltd. has announced that the European Patent Office intends to grant a patent for its next-generation cryoablation technology, specifically the innovative cryogenic connector. This technology is designed to enhance safety and maintain the integrity of cryogen used in procedures. The patent follows similar success in the United States and is expected to bolster IceCure’s intellectual property portfolio, reinforcing its position in the global tumor ablation market. The XSense system has FDA clearance and aims to address additional unmet clinical needs in treating tumors.
Read more →ICCMData on IceCure
IceCure Medical Ltd. has presented positive results from its ICE3 trial for the ProSense® cryoablation system at the Radiological Society of North America's Annual Meeting. The trial showed that ProSense® can be a less invasive treatment option for early-stage low-risk breast cancer, achieving a 5-year recurrence rate similar to that of traditional surgical methods. The FDA Advisory Panel has voted favorably on its benefit-risk profile, with a marketing authorization decision expected in Q1 2025. Dr. Kenneth Tomkovich highlights the significance of these results for the field of radiology and the potential for broader market adoption.
Read more →ICCMIceCure's ProSense Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results Data confirm previous results showing that ProSense cryoablation
IceCure Medical Ltd. announced positive interim results from the ICESECRET study, showing that their ProSense Cryoablation technology achieved an 88.7% recurrence-free rate in the treatment of small renal masses. The findings were presented by Dr. Keren Boguslavsky at the Israeli Urological Association Conference. This minimally invasive method, which uses liquid nitrogen to freeze tumors, provides a crucial alternative for patients unable to undergo kidney-preserving surgery. The study highlights the safety and effectiveness of ProSense in treating both benign and malignant renal tumors.
Read more →ICCMIceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense Cryoablation FDA Marketing Authorization Decision on Early Stage-Low Risk Breast Cancer Expected in Q1 2025
IceCure Medical has reported a significant 36% increase in sales for the first nine months of 2024, attributed to the growing global adoption of its ProSense cryoablation technology. The FDA's Advisory Panel recently voted in favor of ProSense for early-stage, low-risk breast cancer, paving the way for potential marketing authorization in Q1 2025. Additionally, the company's gross profits rose by 41%, and non-GAAP gross profits more than doubled during this period. IceCure aims to enhance its sales infrastructure in anticipation of increased demand following regulatory approval.
Read more →ICCM▲ +9.1%on this newsshared move
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office Invention facilitates treatment of larger tumors and is a significant leap forward in the field of cryoab
IceCure Medical Ltd. has received a Notice of Allowance for its innovative multiprobe cryoablation technology from Japan's Patent Office. This advanced system allows for independent control of multiple cryoprobes, potentially improving the treatment of larger tumors. The company anticipates filing for regulatory approval of its ProSense system for breast cancer in Japan in 2025, in partnership with Terumo Corporation. This development marks a significant advancement in the field of minimally invasive cryoablation procedures.
Read more →ICCMIceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
IceCure Medical Ltd. is set to report its third-quarter financial and operational results for 2024 on November 26, 2024. A press release will be issued before the Nasdaq Stock Market opens, followed by a conference call at 10:00 a.m. EST. The company specializes in cryoablation technology, which serves as a minimally invasive method for tumor treatment. Stakeholders can expect updates on the company’s performance and further developments during this call.
Read more →ICCMIceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including...
IceCure Medical's ProSense® has been selected for the PRECICE study, a significant investigation into cryoablation as an alternative treatment for early-stage breast cancer. Financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, the study is examining the effectiveness of cryoablation in 233 patients over 50 years of age with luminal A and B breast cancer. The study's findings will focus on technical effectiveness, procedure failure rates, and patient quality of life. This represents a notable advancement in the evaluation of less invasive surgical options for early breast cancer treatment.
Read more →ICCM▼ -11.7%on this news· ran to -26% by day 3
FDA Advisory Panel Votes in Favor of IceCure's ProSense Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer FDA decision on marketing authorization expected in the first quarter of 2025
IceCure Medical Ltd.'s ProSense cryoablation system received a favorable recommendation from the FDA Advisory Panel for the treatment of early-stage low risk breast cancer. The panel voted 9-5 in favor of the technology's benefit-risk profile. The FDA is expected to make a decision on marketing authorization by the first quarter of 2025. ProSense represents a minimally invasive alternative to traditional surgical options, which could significantly benefit women seeking treatment.
Read more →ICCM▲ +18.2%on this news
Upcoming FDA Advisory Panel for IceCure
IceCure Medical Ltd. is preparing for an FDA Advisory Panel meeting scheduled for November 7, 2024, to discuss the De Novo marketing submission of its ProSense® Cryoablation System for treating early-stage low risk breast cancer. A significant number of comments from stakeholders, including healthcare professionals and patients, have been posted for the panel's consideration. This meeting will provide expert recommendations on the system's benefit-risk profile prior to the FDA's potential decision in early 2025. IceCure Medical emphasizes the benefits of ProSense® as a safe alternative to traditional surgical tumor removal.
Read more →ICCM▲ +7.5%on this news
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System Innovative cryogenic system connector technology designed to improve usability and maintain the integ
IceCure Medical Ltd. has announced that it received a Notice of Allowance for its Cryogenic System Connector from the U.S. Patent and Trademark Office. This patent is significant for the company's next-generation XSense cryoablation system, which utilizes liquid nitrogen. The system has FDA clearance and aims to address specific unmet needs in the tumor ablation market. IceCure continues to build its patent portfolio and fortify its intellectual property as it commercializes its cryoablation technologies globally.
Read more →ICCMIceCure's ProSense Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference ICE3 trial results presentation by Co-Principal Investigator Dr. Kenneth Tomkovic
IceCure Medical Ltd. announced that its ProSense cryoablation technology was featured in six studies at the 2024 EUSOBI conference, emphasizing its efficacy in treating breast cancer. Dr. Kenneth Tomkovich received the 2024 EUSOBI Abstract Award for his work on the ICE3 trial, which reported a notable 96.3% recurrence-free rate. The conference highlighted the advantages of cryoablation over traditional surgery, including outpatient procedures and minor adverse events. IceCure's ProSense has received growing global interest from medical professionals, further supporting its commercialization efforts.
Read more →ICCMIceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Ra
IceCure Medical Ltd. announced the publication of results from its ICE3 clinical trial, demonstrating a 96.3% recurrence-free rate for early-stage, low-risk breast cancer patients treated with ProSense cryoablation. This significant finding was published in the Annals of Surgical Oncology, highlighting its potential as a safe and effective alternative to surgery. The company expresses optimism regarding future FDA marketing clearance, which could facilitate greater adoption of their technology. The ICE3 trial is noted as the largest controlled multicenter trial in the U.S. for liquid nitrogen-based cryoablation in this treatment area.
Read more →ICCMStudy Published in the British Journal of Radiology Demonstrates IceCure's ProSense is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues Liquid nitrogen- (LN 2 ) ba
IceCure Medical Ltd. announced a study published in the British Journal of Radiology, demonstrating that its ProSense cryoablation procedure has a technical success rate of 97.7% in treating various tumors. Conducted by Dr. Franco Orsi, the study included 85 patients with different types of tumors and showed that only minor complications were reported. The findings indicate that ProSense is a viable alternative to traditional surgical methods, particularly beneficial for patients with multiple comorbidities.
Read more →ICCMIceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense in Early-Stage Low Risk Breast Cancer Scheduled for
IceCure Medical Ltd. announced that the FDA has scheduled an Advisory Panel meeting on November 7, 2024, to discuss the marketing authorization of ProSense for treating early-stage low-risk breast cancer. This meeting aims to gather expert advice on the device's effectiveness and safety, based on significant clinical data, including results from the ICE3 study. The company anticipates receiving FDA clearance for ProSense by early 2025, with the Advisory Panel expected to provide recommendations following the meeting.
Read more →ICCMIceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences
IceCure Medical Ltd. is scheduled to meet with institutional investors at the H.C. Wainwright and Lake Street Capital Markets Conferences. The focus of the presentations will be on the company's ProSense® technology, which provides non-surgical treatment options for benign and cancerous tumors. CEO Eyal Shamir and CFO Ronen Tsimerman will represent the company, with meetings aimed at fostering investor interest. This strategic engagement comes as IceCure continues to market its advanced cryoablation systems globally.
Read more →ICCM▼ -5.4%on this news
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies Further broadens the uses and applications of Ic
IceCure Medical Ltd. announced that it has received a Notice of Allowance from the USPTO for an additional patent related to its cryogenic pump technology. This new patent complements the existing intellectual property held by IceCure, significantly enhancing their cryoablation systems used for tumor treatment. The improvements from this technology enable more efficient procedures and a broader range of applications. IceCure anticipates this development to strengthen its market position, especially with an upcoming FDA decision on early-stage breast cancer treatments expected in early 2025.
Read more →ICCM▲ +18.2%on this news
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets
IceCure Medical reported a 20% increase in sales of its ProSense® systems and probes for the first half of 2024, reflecting greater adoption in various markets, including the U.S. The company anticipates a meeting with the FDA's Medical Device Advisory Committee in Q4 2024 regarding its new treatment for early-stage breast cancer. Positive data from independent studies underlines the efficacy and high satisfaction rates of ProSense® treatments. However, IceCure faces challenges, including reduced sales in China and potential regulatory delays that could affect growth.
Read more →ICCMIceCure's ProSense Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery After a median follow-up of 16 months, the complete ablation rate in Luminal A and B br
IceCure Medical's ProSense cryoablation technology has demonstrated a 100% complete ablation rate for luminal breast cancer tumors in a recent independent study. Conducted in Spain, 43 out of 45 patients accepted the treatment, showing a high acceptance rate among those who chose cryoablation instead of conventional surgery. The study, published in the British Journal of Radiology, indicates that cryoablation is safe, effective, and suitable for elderly patients, opening new possibilities for non-surgical cancer management. These findings suggest a growing demand for ProSense in the treatment of breast cancer.
Read more →ICCMIceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024
IceCure Medical Ltd. will report its financial and operational results for the six months ended June 30, 2024, on August 20, 2024. A press release will be issued before the Nasdaq Stock Market opens, followed by a conference call at 10:00 a.m. EDT. The company specializes in minimally invasive cryoablation technology for tumor treatment. The announcement includes forward-looking statements, indicating potential risks and uncertainties regarding future results.
Read more →ICCMIceCure Announces Positive Data from the Largest Multi- Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials" Investigator initiated independent study include
IceCure Medical Ltd. announced the results of the largest multi-institutional study on cryoablation for primary breast cancer in patients ineligible for clinical trials. This study, published in the American Journal of Roentgenology, involved 112 patients and demonstrated high recurrence-free rates and a low frequency of adverse events. The findings support the use of IceCure's ProSense system as a safe and effective non-surgical option for women with early-stage invasive breast cancer. IceCure has filed for regulatory approval to treat such patients with cryoablation and hormone therapy in the U.S.
Read more →ICCM▼ -6.7%on this news
Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense Cryoablation System: Key Findings Delivered at 32 nd Annual Meeting of the Japanese Breast Cancer Society Demand for minimally invasive br
IceCure Medical Ltd. recently presented encouraging findings from three clinical studies on its ProSense cryoablation system for breast cancer at the 32nd Annual Meeting of the Japanese Breast Cancer Society. The results showed a 99.74% recurrence-free rate in treated patients, suggesting that this minimally invasive technique could serve as an effective alternative to surgical options. Key findings highlighted positive cosmetic outcomes and improved patient satisfaction. IceCure anticipates regulatory approval from Terumo Corporation in early 2025, aiming to expand access to this innovative treatment in Japan.
Read more →ICCM▼ -6.7%on this news
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure
IceCure Medical highlighted promising results from clinical studies of its ProSense® cryoablation technology during the Japanese Breast Cancer Society Annual Meeting. An independent study led by Professor Fukuma showed a 99.74% recurrence free rate over a decade for breast cancer patients treated with ProSense®. Another study by Professor Kawamoto indicated zero local recurrence in a five-year follow-up. The support from Terumo Corporation for regulatory approval anticipated in early 2025 could further increase ProSense®'s market presence in Japan.
Read more →ICCMIceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification CAESAREA, ISRAEL
IceCure Medical has received a notification from Nasdaq indicating that it does not meet the minimum bid price requirement for its continued listing. The company has been given 180 days to achieve compliance by maintaining a bid price of $1.00 per share for ten consecutive business days. During this period, trading of their shares will continue unaffected. If compliance is not achieved within this timeframe, the company may be eligible for a further extension on certain conditions, although failure to meet requirements could risk delisting.
Read more →ICCMDear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Special General Meeting of Shareholders of IceCure Medical Ltd. (the " Meeting "), to be held on Wednesday
IceCure Medical Ltd. is holding a Special General Meeting of Shareholders on August 21, 2024. The board of directors recommends shareholders vote in favor of the proposals listed in the meeting's notice. Shareholders of record as of July 23, 2024, can attend in person or vote by proxy. The meeting aims to engage shareholders and discuss key company matters.
Read more →ICCMEuropean Study Provides More Evidence Supporting IceCure's ProSense is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer Independent, third-party data published in highly influential peer
A recent independent study published in the journal Cancers has validated the safety and effectiveness of IceCure's ProSense cryoablation treatment for metastatic and recurrent breast cancer. Conducted at the University Hospital Frankfurt, the study reported a 100% complete ablation rate with no complications observed in a heterogeneous patient population. Furthermore, the findings suggest that ProSense is a viable outpatient procedure, offering promising outcomes in terms of survival and local tumor control. These results enhance the clinical significance of ProSense across a wider spectrum of breast cancer cases in Europe.
Read more →ICCMU.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes
IceCure Medical Ltd. has received marketing authorization from the U.S. FDA for its next-generation XSense Cryoablation System, which includes cryoprobes. This regulatory clearance validates the efficacy and safety of IceCure's minimally-invasive cryoablation technology, which is designed to address various medical indications. The system is expected to enhance treatment options for conditions such as tumors and skin lesions, while also offering a quick recovery process for patients. The clearance signifies a milestone in IceCure's efforts to innovate and expand its product offerings in the surgical market.
Read more →ICCMIceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024
IceCure Medical will present an overview and updates at the Northland Capital Markets Virtual Growth Conference scheduled for June 25, 2024. The company's management highlights the recent completion of the ICE3 trial and submission of data to the FDA for its ProSense® Cryoablation System aimed at treating early-stage breast cancer. Insider stock purchases reinforce confidence in the company's future, emphasizing the potential of their minimally-invasive technology in oncology treatments.
Read more →ICCMPositive Data from IceCure
IceCure Medical Ltd. announced positive interim results from its ICESECRET trial, highlighting the ProSense® System's safety and effectiveness in treating kidney tumors, achieving an 89.5% recurrence-free rate. The interim data was presented at a conference in Israel, noting that further follow-up data is due in late 2024. Currently approved for treatment in several regions, ProSense® is seen as a promising option within the expanding $6.92 billion global kidney cancer treatment market.
Read more →ICCM▼ -7.6%on this news· ran to -28% by day 3
FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense , Decision Expected Early 2025; Aligns with Commercial Readiness Plan Demonstrates public health importance of assess
IceCure Medical announced that the FDA will convene a Medical Device Advisory Committee to review the De Novo marketing clearance request for its ProSense cryoablation system, aimed at treating early-stage breast cancer. The advisory panel meeting is set for late 2024, with a decision from the FDA anticipated by early 2025. ProSense has demonstrated high effectiveness and patient satisfaction in clinical trials, underscoring its potential as a minimally invasive treatment option. The company aims to leverage this approval process to enhance its commercial efforts in the U.S.
Read more →ICCMIceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024 30% sales growth reflects continued adoption of ProSense in the U.S. and other global markets Major mi
IceCure Medical Ltd. reported a 30% increase in sales of its ProSense cryoablation system for Q1 2024, reflecting growing adoption in the U.S. and international markets. The company completed its ICE3 trial, evaluating ProSense for early-stage breast cancer treatment, and submitted the trial data to the FDA for marketing authorization. Despite this positive momentum, IceCure's total profit decreased compared to the previous year, alongside a decline in gross margin, raising some concerns about financial performance.
Read more →ICCMIceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024
IceCure Medical Ltd. (Nasdaq: ICCM) has announced that it will release its financial and operational results for the first quarter of 2024 on May 28, 2024. The company is known for its ProSense® System, a cryoablation technology used to treat tumors. A conference call will be held the same day to discuss these results and other corporate updates. IceCure operates globally, focusing on a minimally invasive alternative to surgical tumor removal.
Read more →ICCMIceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners
IceCure Medical Ltd. is poised to present significant updates regarding its ProSense® cryoablation technology at the A.G.P / Alliance Global Partners Virtual Healthcare Company Showcase. CEO Eyal Shamir will discuss recent advancements, including the completion of the ICE3 breast cancer trial and ongoing efforts towards FDA clearance. The presentation aims to convey the company's achievements and future business strategies while emphasizing ProSense's role in minimally invasive treatment for tumors.
Read more →ICCMIndependent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense , Adding to Continued Positive Data Published Globally Study published in the pe
IceCure Medical announced that an independent study in Japan demonstrated zero local recurrence of breast cancer five years after treatment with its ProSense cryoablation system. This study followed eighteen early-stage breast cancer patients, showing both safety and high patient satisfaction. The potential for ProSense as a standard treatment for early-stage breast cancer is noted, with regulatory approval in Japan anticipated in the coming months, promising an exclusive market opportunity for the company.
Read more →ICCM▲ +8%on this news
Dear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Annual and Special General Meeting of Shareholders of IceCure Medical Ltd. (the " Meeting "), to be held on Monday
IceCure Medical Ltd. has announced an invitation for its shareholders to attend the Annual and Special General Meeting scheduled for May 20, 2024. The meeting will take place at the company's offices in Caesarea, Israel, and will also be available through remote access. Shareholders are encouraged to vote on the proposals listed in the accompanying notice, with the board of directors recommending support for these measures. To participate, shareholders must be on record by April 22, 2024, to exercise their voting rights.
Read more →ICCM▲ +8%on this news
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Ear
IceCure Medical reported positive outcomes from the ICE3 trial for its ProSense cryoablation technology. The trial demonstrated a 96.3% recurrence-free rate and achieved 100% satisfaction from patients and physicians. Data has been submitted to the FDA for marketing authorization to treat early-stage invasive breast cancer. This innovative approach represents a potential alternative to surgical tumor removal, aiming to enhance patient recovery and minimize risks associated with traditional surgery.
Read more →ICCM▼ -6.7%on this news
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA
IceCure Medical Ltd. reported a 26% increase in sales for its ProSense System and disposables, highlighting a successful transition to a commercial phase. The company completed the ICE3 breast cancer study and plans to submit the data to the FDA for marketing clearance. With promising topline results indicating high local recurrence-free rates, IceCure anticipates strong market interest following FDA approval. The company also gained regulatory approvals in several countries, enhancing its commercial prospects globally.
Read more →ICCMIceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes Continuous innovation as a global leader in minimally invasive liquid-nitrogen based cryoablation systems
IceCure Medical Ltd. has submitted a 510(k) filing to the FDA for its new XSense cryoablation system along with cryoprobes. This system is designed for various indications already covered by the ProSense System, which has received FDA clearance. The XSense System aims to enhance minimally invasive treatments for tumor destruction while expanding IceCure's technology pipeline. The filing is processed separately from an ongoing De Novo application for breast cancer indications.
Read more →ICCMIceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
IceCure Medical Ltd. (Nasdaq: ICCM) announced that it will release its financial and operational results for the year ended December 31, 2023, on April 3, 2024. The CEO and CFO will discuss these results and corporate developments during a conference call at 10:00 a.m. EDT. Additionally, the company will present an overview of its commercial strategy to promote the ProSense® System, a cryoablation technology designed for tumor treatment. This announcement highlights IceCure's commitment to transparency and advancing its market presence.
Read more →ICCMIceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lump
IceCure Medical has reported positive topline results from the ICE3 study, the largest clinical trial of its kind for cryoablation of breast tumors. The trial demonstrated a 96.39% recurrence-free rate among participants, with no significant device-related adverse events. IceCure plans to submit the study results to the FDA in April 2024 for marketing authorization of its ProSense system as an alternative to lumpectomy. This development may increase treatment accessibility for women facing early-stage breast cancer.
Read more →ICCMIceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowed Cryogenic
IceCure Medical Ltd. announced the receipt of a Notice of Allowance from the Japan Patent Office for its Cryogen Flow Control patent. This innovation aims to enhance the efficacy and precision of their ProSense Cryoablation System, which targets tumors through freezing, providing a less invasive alternative to surgical removal. With this patent effective until 2042, IceCure continues to strengthen its intellectual property in key markets including Japan and plans further innovations in cryoablation technologies.
Read more →ICCMIceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
IceCure Medical Ltd. announced that CEO Eyal Shamir will present at the 34th Annual Oppenheimer Healthcare MedTech & Services Conference on March 12, 2024. The presentation will include updates on the ICE3 breast cancer trial and the company's request for FDA marketing clearance for its ProSense® System. This technology offers a minimally invasive treatment option for patients with tumors, emphasizing its advantages over traditional surgical methods. However, the company faces challenges, including pending regulatory approvals and the inherent uncertainties of clinical outcomes.
Read more →ICCMIceCure's ProSense a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 MRI reveals disappearance of hemorrhagic signal and development of necrotic changes Pain reduce
IceCure Medical Ltd. presented results from an independent study on ProSense, a cryoablation technology for extra-pelvis endometriosis, at ECR 2024. Conducted at University Hospital in Nimes, the study involved 7 women who underwent treatment, showing promising results such as the disappearance of hemorrhagic signals and substantial pain relief. All participants reported significant satisfaction, with substantial reductions in pain levels. Despite positive outcomes, the study calls for more extensive research with a larger patient cohort for comprehensive validation.
Read more →ICCMFourth BRIIT Conference in India Features IceCure
IceCure Medical's ProSense® System was prominently featured at the fourth BRIIT conference in Mumbai, India, showcasing advancements in breast cryoablation. Dr. Rupa Renganathan conducted significant sessions highlighting the benefits of cryoablation. With regulatory approval, ProSense® is marketed through Novomed Ltd. in India, leading to increased interest from healthcare providers for its procurement. Experts, including Dr. Hania Bednarski, emphasized the effectiveness and patient advantages of this minimally invasive technology.
Read more →ICCMStudy Using IceCure's ProSense Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer Independent study in women deemed inoperable for breast cancer reports median tumor reduction of 100% at 6 and 12 mont
IceCure Medical announced that an independent study revealed that its ProSense cryoablation treatment resulted in a 100% median tumor reduction in early-stage breast cancer patients at both 6 and 12 months. The study, involving 39 women who were considered inoperable, showed significant tumor size reductions monitored over a year. The results underscore the efficacy of ProSense as a minimally invasive treatment option. IceCure aims to expand the availability of this treatment to more patients worldwide.
Read more →ICCMIceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan IceCure Medical Ltd. (Nasdaq: ICCM) ( IceCure or the Company ), developer of the ProSense® System, a minimally-invasive cryoablation technology...
IceCure Medical Ltd. has announced that its ProSense® System will be featured at two significant medical conferences in Japan, led by Dr. Eisuke Fukuma. The events aim to educate on nonsurgical tumor ablation methods, showcasing clinical data and insights from experienced practitioners. The increased focus on ProSense® could foster improved outcomes for breast cancer patients and promote its adoption as a standard treatment option. Regulatory approval for ProSense® is currently pending in Japan.
Read more →ICCM▲ +7.2%on this news
U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense for Early-Stage Breast Cancer IceCure to submit full 5-year dataset from entire ICE3 study populati
IceCure Medical announced that the U.S. FDA has granted its appeal to reopen the De Novo Classification Request for its ProSense system intended for early-stage breast cancer treatment. The FDA has requested a full 5-year dataset from the ICE3 study, which the company plans to submit by April 2024, ahead of schedule. The ProSense system utilizes cryoablation technology to provide a minimally invasive alternative to traditional surgical methods. IceCure's CEO expressed optimism regarding the potential path to FDA clearance as they prepare to present comprehensive data and comparative analyses to support their case.
Read more →ICCMIceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
IceCure Medical Ltd. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company's ordinary shares have maintained a closing bid price of $1.00 or greater for 10 consecutive business days. This compliance resolves the previous bid price deficiency issue, allowing IceCure to continue its listing on Nasdaq.
Read more →ICCM▲ +6.8%on this newsshared move
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results U.S. sales continue to increase with 25% jump in ProSense system and disposable probe sales in 2023 over
IceCure Medical Ltd. has reported a strong financial performance in preliminary unaudited results for 2023, with a 25% increase in U.S. sales of its ProSense system. The company emphasized the expanding market for cryoablation technology, particularly in large international markets, and highlighted the positive reception of ProSense in academic studies. However, the results also reflect a decrease in revenue from a distribution agreement with Terumo, alongside a recent FDA denial regarding breast cancer indications, which the company is appealing. Despite these challenges, IceCure maintains an optimistic outlook for 2024, anticipating further growth and development.
Read more →ICCM▲ +7.8%on this news
New Study Reports IceCure
IceCure Medical Ltd. has announced the publication of a new study in the journal OncoImmunology, demonstrating that its ProSense® cryoablation technology activates the immune system by enhancing CD8+ T cell response in a mouse model. The findings indicate that cryoablation could offer anti-cancer benefits beyond merely destroying tumors, highlighting its potential to generate sustained immune responses weeks after treatment. This research builds on previous studies, suggesting significant implications for the use of ProSense® in clinical trials for human cancer treatments.
Read more →ICCMStudy Using IceCure's ProSense Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients" Independent study published in Annals of Surgical Oncology concludes cryoablati
IceCure Medical Ltd. announced a study published in the Annals of Surgical Oncology, demonstrating that its ProSense cryoablation system effectively de-escalates surgical therapy for early-stage breast cancer patients. In the study, 32 patients were treated with cryoablation, showing high levels of satisfaction and no major complications. The study reported that all patients were disease-free at follow-up, highlighting cryoablation as a viable non-surgical option for treatment. However, some patients faced complications, including regional disease recurrence in one case.
Read more →ICCM▼ -17.3%on this news
IceCure's ProSense® Deepens Regulatory Approval in India IceCure Medical Ltd. (NASDAQ: ICCM) ( IceCure , IceCure Medical or the Company ), developer of the ProSense® System, a minimally-invasive...
IceCure Medical Ltd. has announced that its ProSense® System has achieved regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) under updated requirements. This approval adds to existing permissions for various medical applications, including oncology and general surgery. The ProSense® system, known for its minimally invasive cryoablation technology, has been effectively utilized in breast cancer treatment since its first procedure in June 2023. IceCure aims to leverage this approval to expand its market presence in India, where it sees substantial growth potential.
Read more →ICCM▲ +83.1%on this newsshared move
IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate Independent study concluded: o IceCure system offers significant advantage in ability to r
IceCure Medical Ltd. announced the successful treatment of kidney cancer tumors using its ProSense System, which achieved a 92% disease-free survival rate and a 100% secondary local control rate, according to a recent independent study. Conducted by a team of physicians in France, the study highlights the safety and efficacy of percutaneous cryoablation in managing small renal masses. The ProSense technology, which utilizes minimally invasive freezing procedures, is already approved for use in multiple countries. The promising findings align with the company's internal research, indicating a strong future for this treatment approach.
Read more →ICCMIceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer Objective is to reopen file to address comments and find appropriate comparator group
IceCure Medical has filed an appeal with the FDA regarding its denied De Novo Classification Request for the ProSense cryoablation technology intended for early-stage breast cancer. The company aims to address the FDA's concerns regarding the comparator group used in evaluating their interim study results. IceCure is hopeful that further analysis may support its eventual marketing authorization. Despite the FDA denial, ProSense remains available for other indicated uses in the U.S. and is approved in various countries worldwide.
Read more →ICCMIceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights
IceCure Medical Ltd. reported its financial results for the nine months ending September 30, 2023, amidst ongoing developments like the ICE3 trial expected to conclude in early 2024. The company highlighted upward sales trends for its ProSense® system and significant regulatory approvals in Brazil and Canada, indicating a broader acceptance of its cryoablation technology. However, the FDA denied a request for breast cancer treatment, prompting the company to appeal the decision. The results from independent studies showcase strong tumor reduction rates, bolstering the product's efficacy and safety profile.
Read more →ICCMIceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023
IceCure Medical Ltd. announced that it will release its financial and operational results for the nine months ending September 30, 2023, on November 15, 2023, prior to market opening. The company will also hold a conference call to discuss these results and further corporate developments at 10:00 a.m. EST that day. The ProSense® System, developed by IceCure, provides a minimally invasive cryoablation technology for tumor treatment, positioning the company within a competitive healthcare landscape. However, the press release also highlights various risks that could impact future operations.
Read more →ICCMSubstantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical
IceCure Medical Ltd. announced significant growth in independent studies of its ProSense® cryoablation technology for treating various tumors, including breast cancer. The ongoing ICE3 study aims to finalize its findings in Q1 2024 with promising interim results showing high recurrence-free rates and full safety. ProSense® has garnered approval in multiple countries, and growing adoption reflects a shift towards minimally invasive surgical alternatives. The company believes that these studies may influence the standard of care for cancer treatments.
Read more →ICCM▼ -5.5%on this news
IceCure's ICE3 Trial Results Demonstrating 96.91% Recurrence Free Rate Featured in a Presentation at BISICON 2023 in India IceCure Medical Ltd. (Nasdaq: ICCM) ( IceCure or the Company ), developer of the ProSense® System, a minimally-invasive cryoablation technology...
IceCure Medical Ltd. presented encouraging interim results from its ICE3 trial at the BISICON 2023 conference. The trial, the largest U.S. controlled study for liquid nitrogen-based cryoablation of early-stage breast cancer, reported a remarkable 96.91% recurrence-free rate and 100% safety. The company's ProSense® System, which allows for minimally invasive procedures, received positive feedback from the medical community. The trial is set to conclude in Q1 2024, and the company aims to expand its technology's availability in India.
Read more →ICCM▼ -5.9%on this newsshared move
Independent Scientific Paper by Doctors Using IceCure
IceCure Medical Ltd. has announced a scientific paper published in the Journal of Breast Imaging, which cites positive interim results from its ICE3 study on cryoablation for early-stage breast cancer. The paper emphasizes the safety and effectiveness of using cryoablation as a minimally invasive alternative to traditional surgical methods. Additionally, it suggests that patients with small, low-risk tumors may benefit most from this approach. The co-authors include recognized professionals in diagnostic imaging, pointing to increasing evidence supporting cryoablation's role in breast cancer treatment.
Read more →ICCM▲ +7.2%on this news
Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical's ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81% Disappearance of lesions and absence of re
IceCure Medical Ltd. announced positive results from an independent study in Italy, demonstrating that women with inoperable breast cancer benefited from its ProSense cryoablation technology. The study involved 28 participants, with results showing tumor reduction rates between 93.43% and 96.81% at various intervals. Notably, all biopsy samples from the Luminal-A group showed no residual malignant cells after treatment. The findings reinforce the effectiveness of ProSense as a non-surgical treatment option for breast cancer patients.
Read more →ICCM▲ +58.3%on this newsshared move
Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate Study was conducted in Spain with women who declined standard of care surgery
IceCure Medical Ltd. announced the successful validation of its ProSense cryoablation technology as a safe and effective outpatient procedure for early-stage breast cancer. A study presented at the EUSOBI Scientific Meeting in Spain demonstrated a success rate of 96.8% among patients who declined traditional surgery. Follow-up care showed minimal progression and no major complications. The results suggest that this procedure could serve as a viable alternative treatment for certain patient populations, particularly the elderly, who prefer less invasive options.
Read more →ICCM▼ -7.5%on this news
Renowned Spanish Radiologist Lucía Graña-López to Present Data Using IceCure Medical
IceCure Medical Ltd. announced that Dr. Lucía Graña-López will present data on their ProSense system, a cryoablation technology for breast tumors, at the upcoming EUSOBI Scientific Meeting in Valencia, Spain. ProSense is approved for treating both malignant and benign tumors throughout the European Union. Dr. Graña-López, a radiologist specializing in breast imaging, will demonstrate the ProSense system and share her experiences with colleagues. The event marks IceCure's first exhibition at EUSOBI, aiming to expand the commercialization of ProSense in Europe.
Read more →ICCM▼ -36.1%on this newsshared move
IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer
IceCure Medical announced that the FDA has denied its De Novo Classification request for the ProSense System, aimed at treating low-risk breast cancer. The FDA's decision does not affect the device's authorization for other indications, which remain available to patients. The company aims to address the FDA's concerns while continuing its ICE3 clinical study, expected to conclude in early 2024. Despite the FDA's denial, the interim analysis of the ICE3 study shows promising low recurrence rates among treated patients.
Read more →ICCMIceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress
IceCure Medical Ltd. will participate in the CIRCE 2023 Annual Congress in Copenhagen, showcasing its ProSense cryoablation system. Key presentations at the symposium will include discussions on the efficacy of cryoablation in various tumors, highlighted by positive results from noted studies. The event will also feature hands-on demonstrations of the ProSense system, aimed at educating attendees. Additionally, IceCure supports women in interventional radiology through a grant to encourage their participation at the conference.
Read more →ICCMIceCure Medical's ProSense Cryoablation System Receives Regulatory Approval in Brazil $6.6 million in sales expected in Brazilian market over the next five years per distribution agreement guarantees High level of early
IceCure Medical's ProSense Cryoablation System has received Class III regulatory approval from Brazil's Health Regulatory Agency (ANVISA). This approval allows the system, which targets a range of oncology applications, to be marketed and sold in Brazil. The company anticipates $6.6 million in sales within five years, reflecting a significant opportunity in a country with a high demand for minimally invasive cancer treatments. Transitioning of ProSense's disposable components to Class III is also expected to be finalized soon.
Read more →ICCMIceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales North America Mr. Shad Good brings nearly 20 years of medical device sal
IceCure Medical has appointed Shad Good as Vice President of Sales for North America, as they prepare for the commercialization of their ProSense System in the region. Good brings nearly 20 years of experience in medical device sales and is expected to build a robust sales structure. The company is awaiting FDA feedback on their De Novo application aimed at expanding the use of ProSense for early-stage breast cancer patients. IceCure aims to enhance their market presence with this strategic appointment amid expectations of strong growth potential.
Read more →ICCMIceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium
IceCure Medical presented its ProSense breast cancer cryoablation technology at the 16th Thai Breast Symposium, highlighting its effectiveness and growing interest from healthcare professionals. Led by Professor Eisuke Fukuma, the symposium showcased ProSense as a minimally invasive alternative to surgical procedures, emphasizing its benefits such as reduced pain and quicker recovery times. The strong partnership with distributor Terumo Corporation is expected to bolster sales in Thailand, further establishing ProSense's positioning in the market. Overall, the event reflects a positive outlook for IceCure's innovative treatment in global breast cancer care.
Read more →ICCMIceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum
IceCure Medical has reported its financial and operational results for the first half of 2023, highlighting a successful transition from clinical to commercial stage with regulatory clearances for its ProSense cryoablation system in Canada and China. The company announced a 9% increase in revenues, with notable growth driven by higher sales in the U.S. and Asian markets. However, the company continues to experience net losses and a decrease in gross profit, primarily due to changes in revenue from its distribution agreement in Japan. Anticipation for FDA approval remains a critical focus as they work to enhance market awareness and accessibility of their technology.
Read more →ICCM▼ -9.6%on this news
IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023
IceCure Medical Ltd. will report its financial and operational results for the second quarter of 2023 on August 14, 2023. The announcement includes a conference call with management and Dr. Robert Ward, an expert user of their ProSense® System. This system is designed for minimally-invasive cryoablation of tumors and is marketed globally. The upcoming discussion will address corporate developments and further details on their operations.
Read more →ICCMHealth Canada Approves IceCure Medical's Minimally Invasive ProSense Cryoablation System Strong interest in ProSense from healthcare providers in Canada strengthens market potential ProSense now approved throughout North
IceCure Medical's ProSense Cryoablation System has received regulatory approval from Health Canada, allowing it to be marketed as a minimally invasive tool for tumor destruction. The company anticipates that this approval will facilitate synergies in the broader North American market, as demand from Canadian healthcare providers has already been noted. The ProSense System, which utilizes liquid nitrogen for cryoablation, has existing approvals in 15 countries, including the U.S., Europe, and China. This expansion into Canada is expected to enhance IceCure's visibility and sales potential in North America.
Read more →ICCM▼ -6.8%on this news
IceCure Medical Expands Distribution of ProSense® into Portugal Through Agreement with Medicinália Cormédica: Upfront Systems & Probes Sales
IceCure Medical Ltd. has announced a non-exclusive distribution agreement with Medicinália Cormédica to supply its ProSense® cryoablation technology in Portugal. The ProSense system, which has received CE mark approval, offers a minimally invasive alternative for tumor treatment and is expected to broaden its market presence in Europe. Initial purchases include two ProSense systems and related disposable equipment, allowing healthcare professionals in Portugal to perform cryoablation procedures effectively.
Read more →ICCMIceCure Medical to Review Recent Progress at Maxim Group
IceCure Medical (Nasdaq: ICCM) will present its ProSense Cryoablation technology at the Maxim Group Healthcare Virtual Conference from June 20-22, 2023. CEO Eyal Shamir will highlight the encouraging interim results from the ICE3 clinical trial, which showed a 96.91% recurrence-free rate and complete patient satisfaction with no adverse cosmetic outcomes. ProSense aims to provide a minimally invasive alternative for patients unsuitable for surgical options. The global tumor ablation market is projected to reach $2.4 billion by 2028, indicating significant growth potential for IceCure's technology.
Read more →ICCMIceCure's ProSense Installation in India is the First to Offer Cryoablation for the Treatment of Breast Cancer in the Country IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors ...
IceCure Medical Ltd. has installed its ProSense® System at Kovai Medical Center and Hospital in Coimbatore, India, marking the first offering of cryoablation for breast cancer treatment in the country. The event was attended by dignitaries, including the Consulate General of Israel, highlighting the significance of this installation. ProSense aims to provide a safer and more effective, minimally invasive treatment option for patients with early-stage breast cancer, contributing to IceCure's global commercial rollout. The system is expected to enhance the dignity and experience of cancer treatment for women in India.
Read more →ICCMIceCure Medical Reports First Quarter 2023 Financial & Operational Results Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses Pr
IceCure Medical Ltd. reported its financial and operational results for the first quarter of 2023, highlighting increased interest in its ProSense System for cryoablation therapy. The company noted consistent engagement with the FDA regarding marketing authorization for ProSense targeting early-stage breast cancer. With a cash position exceeding $20 million, IceCure aims to bolster its commercialization efforts. Despite a slight decrease in revenues and gross profit, there is optimism for further adoption due to recent positive study outcomes and collaborations in the medical community.
Read more →ICCMIceCure to Report First Quarter 2023 Financial & Operational Results on May 22, 2023
IceCure Medical Ltd. (Nasdaq: ICCM) announced that it will release its financial and operational results for Q1 2023 on May 22, 2023. The company will hold a conference call to discuss these results and corporate developments at 10:00 a.m. ET on the same day. IceCure specializes in the ProSense® System, a minimally invasive cryoablation technology for tumor treatment. The call aims to keep investors informed about the company's performance and future plans.
Read more →ICCM▼ -7%on this news
Cryoablation Takes Center Stage at American Society of Breast Surgeons
IceCure Medical Ltd. announced significant interest in its ProSense cryoablation system during the American Society of Breast Surgeons' 24th Annual Meeting. A proposed trial for cryoablation was presented to attendees, highlighting its potential as a minimally invasive alternative to breast surgery. The system received endorsements from ASBrS leadership, and the positive reception indicates a growing acceptance of cryoablation among breast surgeons. This could mark a pivotal moment for the technology in treating early stage breast cancer patients.
Read more →ICCMDear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Annual and Special General Meeting of Shareholders of IceCure Medical Ltd. (the " Meeting "), to be held on Thursday
IceCure Medical Ltd. has announced its Annual and Special General Meeting for shareholders, scheduled for June 1, 2023, via remote communication on ZOOM. Shareholders of record as of May 4, 2023, are entitled to participate and vote on various proposed resolutions. The board recommends voting 'FOR' these proposals, indicating support for the company’s strategic direction.
Read more →ICCMIceCure Medical to Provide Educational Support in a First-of-its-Kind Cryotherapy Course at the American Society of Breast Surgeons
IceCure Medical Ltd. is set to provide educational support for a pioneering cryotherapy course at the American Society of Breast Surgeons' 24th Annual Meeting. The course will feature hands-on training for physicians utilizing IceCure's ProSense® system, aimed at promoting awareness of breast cryoablation. Key interim results from the ICE3 trial, which show low recurrence rates of cancer, will be highlighted, signaling positive outcomes for the minimally invasive treatment method. IceCure anticipates that increased physician education will enhance the adoption of ProSense as a viable alternative for early-stage breast cancer patients awaiting regulatory approval from the FDA.
Read more →ICCM▲ +11.1%on this newsshared move
IceCure's ProSense System Used in Endometriosis Cryoablation Study That Demonstrated Efficacy Rate of 92.8% to Avoid Secondary Surgery ProSense System among the two types of systems used in the study Pain-free survival r
IceCure Medical's ProSense System has been utilized in a study at Sorbonne University, demonstrating an impressive efficacy rate of 92.8% in avoiding secondary surgery for patients with symptomatic extraperitoneal endometriosis. The study concluded that percutaneous cryoablation is a safe and effective method for pain reduction and local control of the condition. Led by Dr. Francois H. Cornelis, the research highlighted the importance of minimally invasive techniques in treating endometriosis, an often-chronic condition affecting many women. The ProSense system is already cleared for use in several countries, adding to its credibility.
Read more →ICCMIceCure Medical Ordinary Shares to Trade Exclusively on Nasdaq: Company to Voluntarily Delist Shares from Trading on the Tel Aviv Stock Exchange
IceCure Medical Ltd. has announced its decision to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange, effective July 24, 2023. The company will continue to trade exclusively on the Nasdaq Capital Market under the ticker symbol ICCM. This strategic move aims to reduce listing costs and focus on the U.S. capital markets while affirming IceCure's commitment to its existing Israeli shareholders. The company specializes in minimally invasive cryoablation technology for tumor treatment.
Read more →ICCM▼ -8.6%on this news
IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to Drive Revenue Growth in 2023 Rising Utilization of ProSense in the U.S. Market Generates Year-o
IceCure Medical reported its financial results for 2022, highlighting a decline in total revenue from $4.1 million to $3.1 million. However, the company anticipates significant revenue growth in 2023, mainly due to increased utilization of its ProSense system in the U.S. Markets. Key corporate developments include a distribution agreement with Medtronic for commercialization in China and rising sales of disposable cryoprobes. Despite a reported net loss of approximately $17.0 million, IceCure remains optimistic about its revenue-driving strategies and expanded marketing efforts for its cryoablation technology.
Read more →ICCM▲ +14.3%on this newsshared move
IceCure Medical Receives Regulatory Approval in China for Commercial Use of its IceSense3 Disposable Cryoprobes This approval allows the use of the IceSense3 disposable cryoprobes in combination with the Company's IceSen
IceCure Medical has received regulatory approval from China's National Medical Products Administration for its IceSense3 disposable cryoprobes, enabling commercial use alongside the previously approved IceSense3 console. This marks a significant advancement for the company's minimally invasive cryoablation technology targeting various types of tumors, including those of the breast, lung, and kidneys. With approximately 430,000 new breast cancer cases reported in China in 2022, IceCure sees a promising market opportunity. The company anticipates monetizing its distribution agreements effectively following this approval.
Read more →ICCMIceCure Medical to Report 2022 Full Year Financial & Operational Results on March 29, 2023
IceCure Medical Ltd. is scheduled to report its full-year financial and operational results for 2022 on March 29, 2023. The company develops minimally-invasive cryoablation technology, notably the ProSense® System, which treats tumors by freezing rather than through surgical removal. Prior to the market opening on the reporting date, IceCure will host a conference call to discuss the details of the results and any related corporate developments.
Read more →ICCMDear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Special General Meeting of Shareholders of IceCure Medical Ltd. (the " Meeting "), to be held on Monday
IceCure Medical Ltd. has scheduled its Special General Meeting of Shareholders for April 10, 2023, at 4:00 p.m. Israel time, which will be held remotely via ZOOM. Shareholders of record as of March 8, 2023, are invited to attend and vote on key proposals recommended by the board of directors. The meeting aims to foster shareholder engagement and decision-making regarding corporate resolutions.
Read more →ICCMIceCure Medical Announces Preliminary Unaudited 2022 Year-End Financial Results & Recent Operational Highlights Significant regulatory and reimbursement milestones achieved Positive interim clinical results for ProSense
IceCure Medical has announced its preliminary unaudited financial results for 2022, reporting a revenue decline to $3.1 million. The company achieved significant regulatory milestones, including a $3,400 CPT Category III code for breast cancer cryoablation. Interim clinical results from their ProSense treatment indicated an 89.5% recurrence-free rate for kidney tumors. Despite sales declines in most territories, IceCure showed a 28% increase in U.S. sales and maintains a strong cash position of $23.6 million.
Read more →ICCMIceCure's ProSense Featured in Breast Session at the Society of Interventional Oncology's Annual Scientific Meeting in Washington, D.C. IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ( IceCure or the Company ), developer of minimally-invasive cryoablation technology, the ProSense® ...
IceCure Medical Ltd. participated in the Society of Interventional Oncology's Annual Scientific Meeting, showcasing its ProSense cryoablation system. The system, which treats tumors by freezing, was highlighted in a panel discussion and drew attention from medical professionals. Notably, ICE3 interim trial results were mentioned, indicating growing interest among practitioners in treating breast cancer using cryoablation. The ProSense technology is positioned as a minimally invasive alternative to traditional surgical methods for tumor treatment.
Read more →ICCMU.S. Patent Office Grants Notice of Allowance to IceCure for Novel Cryogenic Pump for Next-Generation Cryoablation Systems Patent has also been granted or allowed in major markets, including the European Union and Japan
IceCure Medical Ltd. has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent on a novel cryogenic pump, which is set to bolster its cryoablation systems. This patent is effective until February 2040 and has also been granted in the European Union and Japan. The new technology aims to provide a broader range of clinical applications with improved efficiency, contributing to IceCure's growth in minimally invasive treatments. The company is optimistic about its market potential in the U.S., particularly in breast cancer indications following its recent regulatory filing.
Read more →ICCM▲ +6.3%on this newsshared move
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems Innovating as a global leader in cryoablation technologies, with 29 patents issued and allowed
IceCure Medical Ltd. has received a Notice of Allowance for a patent on its novel cryogenic pump from the Japan Patent Office. This patent, effective until 2041, is part of the company’s effort to bolster its next-generation cryoablation systems. The innovative pump is designed to enhance procedure efficiency by allowing longer use without needing to refill liquid nitrogen, thereby expanding the potential clinical applications of cryoablation therapies. IceCure continues to build its leadership in the minimally invasive tumor treatment market with this development.
Read more →ICCMIceCure Medical CEO Issues Letter to Shareholders
IceCure Medical, a developer of minimally-invasive cryoablation technology, published a letter to shareholders highlighting key achievements in 2022. CEO Eyal Shamir emphasized the company's commitment to establishing ProSense as a new standard in tumor therapy through its innovative procedures. IceCure's progress includes solid clinical data on breast and kidney cancer therapies, enhanced partnerships, and a focus on upcoming opportunities in 2023. Despite optimistic projections, the company acknowledged potential risks associated with future regulatory responses and market dynamics.
Read more →ICCM▲ +6.1%on this news· ran to +27% by day 1
IceCure Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market CAESAREA, Israel, December 23, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the
Read more →ICCM▼ -46.9%on this newsshared move
IceCure Medical Ltd. Announces Pricing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Ltd. Announces Pricing of $14.5 Million Public Offering Priced At-The-Market CAESAREA, Israel, December 21, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSens
Read more →ICCM▲ +177.6%on this newsshared move
IceCure Medical Ltd. Announces Proposed Public Offering
CAESAREA, Israel, Dec. 20, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the commencement of a pro
Read more →ICCMIceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results ICESECRET study interim findings presented at the Urological Association Conference in Eilat,
IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results CAESAREA, Israel, December 19, 2022 -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive
Read more →ICCMIceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors Galit Bar Malik promoted to VP of Operations and Service
IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors Galit Bar Malik promoted to VP of Operations CAESAREA, Israel, December 6, 2022 -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of
Read more →ICCMIceCure Medical Reports Financial Results for the Nine Months Ended
Medical Reports Financial Results for the Nine Months Ended September 30, 2022 and Provides Update on Recent Operational Highlights Israel, December 5, 2022 -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoabl
Read more →ICCMIceCure's ProSense Featured in Poster Presentation at Radiological Society of North America's 2022 Annual Meeting Dr. Kenneth Tomkovich Presents: "To Freeze Or Not To Freeze? That Is The Question: Cryoablation For The Tr
ProSense Featured in Poster Presentation at Society of North America's 2022 Annual Meeting Israel, November 30, 2022 -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense System t
Read more →ICCMTIME CHANGE: IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022
CAESAREA, Israel, Nov. 29, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor remova
Read more →ICCMIceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022
CAESAREA, Israel, Nov. 28, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor remova
Read more →ICCM▲ +10.6%on this news
IceCure's ProSense Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures Receives assignment to a Medicare Payment Group for hospital outpatient payment Marks CMS's first payment assignment for
ProSense Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures Israel, November 8, 2022 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense System that
Read more →ICCMIceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month
ProSense® minimally invasive breast cancer procedure destroys tumors, freezing cancer in its tracks, empowering women to walk out of the procedure and back to their lives CAESAREA, Israel, Oct. 26, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure"
Read more →ICCM▲ +8.5%on this news
IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery 43,000 cases estimated a
IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery Israel, October 19, 2022 -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("Ic
Read more →ICCMIceCure Submits Regulatory Filing in Vietnam for Approval of ProSense Company is rapidly expanding its global regulatory and commercial reach
Regulatory Filing in Vietnam for Approval of ProSense Company is rapidly expanding its global regulatory and commercial reach CAESAREA, Israel, August 29, 2022 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cr
Read more →ICCM▲ +5.2%on this news
IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights Conference call scheduled for 4:30 p.m. EDT today Exclusive distribution agreement signed with Shanghai Medtronic Zhi
IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights Israel, Aug. 15, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology,
Read more →ICCMIceCure Medical to Report H1 2022 Results and Conduct Conference Call on August 15, 2022
CAESAREA, Israel, Aug. 9, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal
Read more →ICCMDear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Special General Meeting of Shareholders of IceCure Medical Ltd. (the " Meeting "), to be held on
Dear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Special General Meeting of Shareholders of IceCure Medical Ltd. (the "Meeting"), to be held on September 1, 2022 at 4:00 p.m. Israel time (9:00 a.m. Eastern Time), by means of remote communication, i
Read more →ICCMIceCure Announces Regulatory Filing Submission for Approval of ProSense in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors Canadian hospitals and health care providers have expressed stron
Regulatory Filing Submission for Approval of ProSense in Canada for Indications Including Ablation of Benign and Malignant Breast Canadian hospitals and health care providers have expressed strong interest in ProSense as they seek minimally invasive treatments for breast and ot
Read more →ICCMCorporate Presentation | July 2022 Freezing cancer in its tracks (NASDAQ & TASE: ICCM) icecure - medical.com IceCure Medical enabling non-surgical, treatment of cancerous tumors Nasdaq & TASE: ICCM Forward Looking Statem
Corporate Presentation | July 2022 Freezing cancer in its tracks (NASDAQ & TASE: ICCM) icecure - medical.com IceCure Medical enabling non-surgical, treatment of cancerous tumors Nasdaq & TASE: ICCM Forward Looking Statement Disclaimer: IMPORTANT : The following applies to this d
Read more →ICCMFormer Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Market Operations
A global medical device industry expert with a focus on market creation and fast growth, Mr. Glick has led Itamar Medical, Inc. ("Itamar Medical") as CEO, building its medical device business for a decade until Itamar Medical's acquisition by Zoll Medical for $538 million CAESAR
Read more →ICCMIceCure's ProSense® Featured at SIR 2022 Annual Meeting in Breast Cancer Cryoablation Categorical Course IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ( IceCure or the Company ), developer of minimally-invasive cryoablation technology, the ProSense® ...
Strong interest in ProSense from potential customers and distributors spurred by categorical course and Shanghai Medtronic deal CAESAREA, Israel, June 15, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-i
Read more →ICCMIceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China Shanghai Medtronic to exclusively distribute IceSense3 cryoablation systems with a minimum purchase target of $3.5 millio
Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China First IceSense3 systems to be delivered in 2022 CAESAREA, Israel, June 13, 2022 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive c
Read more →ICCMIceCure Medical's ProSense Cryoablation System Submitted for Regulatory Approval in Brazil Regulatory filing submitted by KTRFIOS, IceCure's distributor in Brazil Filing includes breast and other cancers, benign tumors,
Medical's ProSense Cryoablation System Submitted for Regulatory Approval in Brazil June 9, 2022 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tumors
Read more →ICCM▼ -8.5%on this news
IceCure Medical Reports First Quarter 2022 Financial Results and Operational Highlights Conference call scheduled for 8:30 am ET today hosted by management with guest Dr. Richard Fine Increased commercial activity in the
Medical Reports First Quarter 2022 Financial Results and Operational Highlights Israel, May 18, 2022 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tu
Read more →ICCMIceCure Medical to Report Q1 2022 Results and Conduct Conference Call May 18, 2022
CAESAREA, Israel, May 11, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor remova
Read more →ICCMIceCure Medical Presents ICE3 Breast Cancer Trial Interim Data, Hosts Cryoablation Symposium & Conducts Hands-On ProSense® Training Sessions at the European Conference on Interventional Oncology
CAESAREA, Israel, April 27, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor remo
Read more →ICCM▼ -7.4%on this news
IceCure Medical Ltd. ("the Company") Compensation Policy for Company's Office Holders Dated: March 2022 Introduction 1.1 Pursuant to the provisions of the Companies Law, 1999 (hereafter - " the Companies Law "), on
Policy for Company's Office Holders holder- as defined in the Companies Law- 5759-1999, i.e., Chief Executive Officer (CEO), deputy CEO, Directors, Chairmen, Subordinate office holder, any person filling any of these positions in the Company even if he holds a different title,
Read more →ICCMCorporate Presentation | February 2022 Freezing cancer in its tracks (NASDAQ & TASE: ICCM) icecure - medical.com IceCure Medical enabling non-surgical, treatment of cancerous tumors Nasdaq & TASE: ICCM Forward Looking St
Corporate Presentation | February 2022 Freezing cancer in its tracks (NASDAQ & TASE: ICCM) icecure - medical.com IceCure Medical enabling non-surgical, treatment of cancerous tumors Nasdaq & TASE: ICCM Forward Looking Statement Disclaimer: IMPORTANT: The following applies to thi
Read more →ICCMCorporate Presentation | February 2022 (NASDAQ & TASE: ICCM) icecure - medical.com Freezing cancer in its tracks IceCure Medical enabling non-surgical, treatment of cancerous tumors N as d aq & TA S E : I CC M Forward Lo
Corporate Presentation | February 2022 (NASDAQ & TASE: ICCM) icecure - medical.com Freezing cancer in its tracks IceCure Medical enabling non-surgical, treatment of cancerous tumors N as d aq & TA S E : I CC M Forward Looking Statement N as d aq & TA S E : I CC M 2 Disclaimer: I
Read more →ICCM▲ +10.9%on this news· ran to +36% by day 3
IceCure Medical Announces Preliminary Unaudited 2021 Year-End Financial Results Revenue increase driven by sales through distribution agreements for IceCure's groundbreaking minimally-invasive cryoablation tumor destruct
Announces Preliminary Unaudited 2021 Year-End Financial Results CAESAREA, Israel, January 31, 2022 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tumo
Read more →ICCMIceCure Medical CEO Issues Letter to Shareholders CAESAREA, Israel, January 5 th , 2022 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation techn
CEO Issues Letter to Shareholders CAESAREA, Israel, January 5th, 2022 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tumors by freezing as an alternat
Read more →ICCM▼ -10.5%on this news
IceCure Medical Receives Notice of Intention to Grant a European Patent Covering Its Cryogenic Pump
Medical Receives Notice of Intention to Grant a European Patent Covering Its Cryogenic Pump Israel, December 20, 2021 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense System,
Read more →ICCM▼ -11.1%on this news
IceCure Medical Ltd. Closes $17 Million Underwritten Public Offering and Partial Exercise of Over-Allotment Option Caesarea, Israel
IceCure Medical Ltd. Closes $17 Million Underwritten Public Offering and Partial Exercise of Over-Allotment Option Caesarea, Israel, December 13, 2021 - IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM.TA) (the "Company" or "IceCure"), developer of minimally-invasive cryoablat
Read more →ICCM▼ -19.4%on this newsshared move
IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering Caesarea, Israel, December 9 th , 2021 - IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM.TA) (the " Company " or " IceCure "), developer
IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering Caesarea, Israel, December 9th, 2021 - IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM.TA) (the "Company" or "IceCure"), developer of minimally-invasive cryoablation technology, the ProSense Sy
Read more →ICCM▼ -9.8%on this newsshared move
IceCure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources - New executive appointment made commensurate with IceCure's growth related to the increased adoption of its flagship ProSense Cr
Announces Appointment of Merav Nir Dotan to Vice President Human Resources CAESAREA, Israel, November 29, 2021 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense System, that d
Read more →ICCM▼ -5.8%on this news· ran to -19% by day 3shared move
IceCure Medical Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments
Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments November 23, 2021 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of next-generation, minimally-invasive cryoablation technology w
Read more →ICCMIceCure Medical Announces New Independent Data Published in the Journal of Cancer Therapy Showing that Percutaneous Cryoablation Presents a Potential Substitute for Lumpectomy for Tumors <15mm using ProSense™
CAESAREA, Israel, Nov. 1, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article
Read more →ICCM▲ +5.7%on this news· ran to +24% by day 3
IceCure Medical Enters into an Exclusive Agreement in Poland for Distribution of the ProSense™ Cryoablation System
CAESAREA, Israel, Oct. 20, 2021 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that it has entered into an
Read more →ICCMIceCure Medical Announces Updated Regulatory Strategy in China for the IceSense3 System to Treat Cancerous Tumors with Cryoablation - - - IceCure submitted an amendment to the registration certificate granted for the Ice
Medical Announces Updated Regulatory Strategy in China the IceSense3 System to Treat Cancerous Tumors with Cryoablation submitted an amendment to the registration certificate granted for the IceSense3 System by China's NMPA, which will allow IceCure to sell its IceSense3 and C
Read more →ICCMIceCure Medical Reports Financial Results for the First Half of 2021 and Recent Operating Highlights
Medical Reports Financial Results for the First Half of 2021 and Recent Operating Highlights Israel, September 23, 2021 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology
Read more →ICCMIceCure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the ICE3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer
CAESAREA, Israel, Sept. 13, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that the first peer review
Read more →ICCMIceCure Medical Announces Exclusive Distribution Agreement to Sell ProSense Cryoablation System in Turkey
IceCure Medical Announces Exclusive Distribution Agreement to Sell ProSense Cryoablation System in Turkey September 1, 2021 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation techno
Read more →ICCMIceCure Medical Shares to Begin Trading on Nasdaq Capital Market on
IceCure Medical Shares Nasdaq Capital Market August 26, 2021 -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that its
Read more →ICCMIceCure Announces 8-for-1 Reverse Stock Split in Preparation for Nasdaq Listing
CAESAREA, Israel, Aug. 9, 2021 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, yesterday announced that it has implemented an 8-for-1 reve
Read more →ICCMIceCure Medical Announces Exclusive $6.6M Distribution Agreement to Sell ProSense™ Cryoablation System in Brazil
CAESAREA, Israel, June 7, 2021 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that it has entered into an exclusive distr
Read more →ICCMPositive Interim Results from IceCure Medical
CAESAREA, Israel, May 4, 2021 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the minimally invasive cryoablation ProSense® System that destroys tumors by freezing, today announced interim results from the Company's ICE3 clinical trial
Read more →ICCMIceCure Medical Announces Upcoming Presentation at the American Society of Breast Surgeons Annual Meeting
CAESAREA, Israel, April 20, 2021 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, announced that updated clinical data from its ICE3 clinic
Read more →ICCMIceCure Medical Granted FDA Breakthrough Device Designation for ProSense® Cryoablation System
CAESAREA, Israel, April 5, 2021 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation cryoablation technology that destroys tumors by freezing, announced today that it has been granted Designation as a Breakthrough Device
Read more →ICCMIceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East
CAESAREA, Israel, Feb. 17, 2021 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation cryoablation technology that destroys tumors by freezing without the need for surgery, today announced an exclusive distribution agreem
Read more →ICCMIceCure Announces a $15 Million Private Placement and Intention to Pursue NASDAQ Listing
IceCure Medical Ltd. has announced a $15 million private placement to support its plans for a NASDAQ listing. The funding will facilitate the commercialization of its ProSense cryoablation system and accelerate product development. The company has experienced significant sales growth and is making progress in clinical trials, with interim results expected later this year.
Read more →ICCMIceCure Inks Expanded Distribution Agreement with Terumo Corporation for Thailand
Expanded Agreement Builds from the Success of its Current Joint Activities in Japan and Singapore, to Bring its Cryoablation Products to Benefit More Patients in Asia CAESAREA, Israel, Jan. 5, 2021 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM), developer of the next generati
Read more →ICCMIceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million
CAESAREA, Israel, Oct. 5, 2020 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM), developer of the next generation cryoablation technology that destroys tumors by freezing without the need for surgery, today announced that it has expanded its strategic partnership with Terumo Cor
Read more →ICCMIceCure Raises NIS 20.7 Million in Equity Share Offering; Received Oversubscribed Demand of NIS 24 Million
CAESAREA, Israel, Aug. 10, 2020 /PRNewswire/ -- IceCure Medical (Tel Aviv: ICCM) a leading medical device company that markets a non-surgical Liquid Nitrogen (LN2) cryoablation technology to destroy benign and cancerous tumors, today announced that it has completed a NIS 20.7 mil
Read more →ICCMIceCure's Global Expansion Accelerates; Tumor Freezing Product Now Approved for Market in India IceCure Medical (TA: ESCM), a developer and marketer of minimally-invasive cryoablation therapies for the women's health and interventional oncology...
CAESAREA, Israel, April 28, 2020 /PRNewswire/ -- IceCure Medical (TA: ESCM), a developer and marketer of minimally-invasive cryoablation therapies for the women's health and interventional oncology markets, today announced that a license has been granted by the Indian regulatory
Read more →ICCMIceCure Enters German Cryoablation Oncology Market; Inks Exclusive Distribution Agreement With MTS Medical Technology
CAESAREA, Israel, April 22, 2020 /PRNewswire/ -- IceCure Medical (TASE: ICCM), a developer and marketer of minimally invasive cryoablation therapies for women's health and interventional oncology markets, has entered into an exclusive distribution agreement with MTS Medical Techn
Read more →ICCMIceCure Continues Global Expansion to Freeze Tumors
CAESAREA, Israel, April 20, 2020 /PRNewswire/ -- IceCure Medical (TASE: ICCM), a developer and marketer of minimally invasive cryoablation therapies for women's health and Interventional oncology markets, announced today the expansion of its distribution territory into Singapore
Read more →ICCMIceCure Medical Continues Expansion in Asia; Receives Largest Purchase Order for ProSense™ Cryoablation System
CAESAREA, Israel, April 1, 2020 /PRNewswire/ -- IceCure Medical Ltd (TASE: ICCM), a developer and marketer of minimally invasive cryoablation therapies for women's health and Interventional oncology markets, announced today that it has received its largest purchase order (PO) for
Read more →ICCMIceCure Receives FDA Clearance for Expanded Indications of Cryoablation Technology and Regulatory Approval of New MultiSense System; Plans to Increase U.S. Presence and Operations
CAESAREA, Israel, Jan. 7, 2020 /PRNewswire/ -- Following the additional U.S. Food and Drug Administration (FDA) clearance for its Cryoablation Technology, IceCure Medical Ltd. (TASE: ICCM), an Israeli medical device company, developers of a non-surgical Liquid Nitrogen (LN2) cryo
Read more →ICCMIceCure Medical Appoints Medical Device Veteran Sharon Levita to its Board of Directors
CAESAREA, Israel, Dec. 2, 2019 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM), a developer of the next generation cryoablation technology to treat malignant and benign tumors by freezing without the need for surgery, announced the appointment of Ms. Sharon Levita to the Compan
Read more →ICCMIceCure Medical Announces Landmark Strategic Deal With Global Medical Company, Terumo Corporation
CAESAREA, Israel, Sept. 3, 2019 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM), developer of the next generation cryoablation technology to treat malignant and benign tumors by freezing without the need for surgery, announced today an exclusive distribution agreement with lead
Read more →ICCMAnother Success: IceCure Receives Israeli AMAR Approval for Use of its Freezing Technology in Specific Indications, Following an Earlier General Approval
CAESAREA, Israel, Aug. 5, 2019 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM), an Israeli medical device company that has developed a minimally-invasive cryoablation technology to treat malignant and benign tumors by freezing without the need for surgery, has received Israeli
Read more →ICCMIceCure Medical Announces New Category III CPT Code for Breast Cryoablation Therapy, Issued by the American Medical Association
CAESAREA, Israel, July 2, 2019 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM), developer of the next generation liquid-nitrogen-based cryoablation technology to treat malignant and benign tumors by freezing, announced today that its application for a new CPT code, describing t
Read more →ICCMIceCure Medical Presents Promising Results from First-ever Interventional Radiology Study With Its Next Generation Liquid Nitrogen (LN2) Cryoablation System, ProSense™
CAESAREA, Israel, March 20, 2019 /PRNewswire/ -- IceCure Medical, developer of the next generation liquid-nitrogen-based cryoablation technology to treat tumors by freezing, today announced promising results from its first-ever interventional radiology study. Marking kidney canc
Read more →ICCMNew Non-Surgical Treatment Freezes Breast Cancer in its Tracks
In the ICE3 cryoablation of breast cancer trial, a liquid nitrogen cooled probe is inserted into the tumor under ultrasound guidance. The super cooled probe freezes the water in the cancer cells creating an ice ball (demonstrated with water in photo). The freezing of the tumor ce
Read more →Competitive Position
How ICCM ranks across every disease it competes inCompetitive Position is a premium feature
See how ICCM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial